Synthesis of β - and γ -Hydroxy α -Amino Acids via Enzymatic Kinetic Resolution and Cyanate-to-Isocyanate Rearrangement

Piotr Szcześniak,[†] Agnieszka Październiok-Holewa,[‡] Urszula Klimczak,[†] and Sebastian Stecko^{*,†}

[†]Institute of Organic Chemistry, Polish Academy of Sciences, Kasprzaka 44/52, 01-224 Warsaw, Poland

[‡]Department of Organic Chemistry, Bioorganic Chemistry and Biotechnology, Silesian University of Technology, Krzywoustego 4, 44-100 Gliwice, Poland

Supporting Information



ABSTRACT: A new strategy for stereoselective preparation of all four isomers of β - and γ -hydroxy α -amino acids is presented. The developed procedure is based on enzymatic kinetic resolution and cyanate-to-isocyanate rearrangement as key steps. Stereocontrol is achieved by proper choice of the starting hydroxyacid, the course of kinetic resolution, and the stereospecific signatropic rearrangement step, which proceeds with full chirality transfer.

INTRODUCTION

 β - and γ -hydroxy α -amino acids are important structural motifs of numerous naturally occurring molecules exhibiting interesting pharmacological properties.¹⁻⁸ An excellent example of this class of compounds is threonine and its three isomers. L-Threonine can be found in several polypeptide drugs such as sermoreline, used for the treatment of dwarfism,⁹ ceruletide, a smooth muscle and digestive secretions stimulator,¹⁰ exenatide, which is a GLP-1 antagonist for treatment of diabetes mellitus type 2,¹¹ or enfuvirtide, an HIV fusion inhibitor.¹² D-Threonine is also a structural motif in various natural products.⁴⁻⁶ The diastereomers of threonines, allo-threonines, are also widespread in nature, as representatives of nonproteinogenic amino acids. L- and D-allo-threonine motifs were found in bioactive peptides, for instance antiviral viscosin,¹³ antibiotic hormao-mycin,¹⁴ antitumor astins¹⁵ and phytotoxic syringopeptins.¹⁶ Also other hydroxy amino acids, such as β -phenyl serines, β hydroxyleucines, or β -hydroxytyrosines, are found in the structure of a number of cyclic polypeptides active against HIV (e.g., callipeltines,¹⁷ neamphamide,¹⁸ papuamides,¹⁹ mirabamides,²⁰ and celebesides²¹). Another non-natural amino acid, (2R,3R)- β -cyclohexyl-serine, constitutes a part of aplaviroc (GSK-873140), a CCRS antagonist used in the treatment of HIV infection.²² Finally, β -phenylserine and β hydroxytyrosine are present in antibiotics such as vancomycin,²³ bouvardin,²⁴ chloramphenicol,²⁵ hypeptin²⁶ and katanosins.²⁷

Functionalized β - and γ -hydroxy α -amino acids are not only attractive building blocks for the synthesis of complex organic

molecules 28 but also used as chiral catalysts and ligands 29 for enantioselective transformations. 30

The importance of hydroxylated α -amino acids, either as a structural element of bioactive peptides or as intermediates in the synthesis of complex molecules and catalysts, resulted in the development of a multitude of methods for their asymmetric synthesis. Typical approaches for the preparation of hydroxylated amino acids are based on Sharpless asymmetric dihydroxylation or epoxidation of allyl alcohols,³¹ catalytic hydrogenation of α -amino- β -keto esters,³² aldol reaction,³³ biocatalyzed transformations,³⁴ and others.^{35–37}

Since all isomeric (enantiomeric and diasteromeric) forms of hydroxy amino acids are interesting from a biological as well as a synthetic point of view, synthetic protocols that enable the preparation of all four isomers are desirable. Herein, we report an efficient method for the selective preparation of diastereomeric hydroxy amino acids from simple precursors, hydroxy carboxylic acids, via an enzymatic kinetic resolution and enantiospecific cyanate-to-isocyanate sigmatropic rearrangement reaction sequence.

RESULTS AND DISCUSSION

The key feature of our proposal is the stereoselective formation of allyl alcohols 2a,b from the corresponding chiral hydroxyacid with a general structure represented by 1 and the transformation of 2a,b into allylamines 3a,b by a sigmatropic rearrangement, as outlined in Scheme 1.

Received: October 19, 2014 Published: November 11, 2014 Scheme 1



The concerted nature of the rearrangement step should transpose the stereogenic center with full chirality transfer to provide the corresponding allylamine regardless of the configuration of the other stereocenter, originating from the starting hydroxyacid. Thus, varying the configuration of the initial hydroxyacid and employing independent stereoselective generation of a second allylic stereogenic center should enable the furnishing of isomeric hydroxy allylamines after the sigmatropic rearrangement. Simple transformations of the double bond in hydroxy allylamines (3) will allow access to the corresponding hydroxy amino acids and their derivatives.

Our first efforts were directed toward the synthesis of Lthreonine and its isomers starting from methyl L- and D-lactate. Thus, methyl L-lactate was O-silylated with TBSCl to afford ester 4a, which was converted into enone 5a via a one-pot reduction and Horner–Wadsworth–Emmons olefination³⁸ sequence in 80% after 2 steps (Scheme 2).

Scheme 2

OH ₹ COOMe	TBSCI imidazole CH ₂ Cl ₂ , rt	OTBS R COOMe 4a R = Me, 80% 4b R = Ph, 87% 4c R = Bn, 65%	1) DIBAL-H, CH ₂ Cl ₂ -78 °C 2) NaH O R OMe OMe THF, 0 °C	OTBS R 5a R = Me, 80% 5b R = Ph, 86% 5c R = Bn, 70%
			1111,00	BOIN DI, 107

Next, we focused on the stereoselective transformation of enone **5** into alcohols **6** and **7**. Disappointingly, Corey– Bakshi–Shibata reduction³⁹ of enone **5a** with BH₃·Me₂S in the presence of chiral oxazaborolidine (S)-8 yielded a hardly separable mixture of alcohols **6a** and **7a** in a 4:1 ratio (Scheme 3). Lowering the reaction temperature from -30 to -78 °C did not increase the reaction selectivity. Therefore, due to lack of synthetic attractiveness, this approach to the synthesis of diastereomeric alcohols **6** and **7** was rejected.

Searching for an effective method of stereoselective synthesis of alcohols of type 6 and 7, we turned to enzymatic kinetic resolution⁴⁰ of diastereomeric alcohols 9. For this purpose,

Scheme 3

OTBS	HPh N-B BH ₃ TI THF, -30	Ph (10 mol% 8 HF → 0 °C	6) R OH	+ R	TBS
5a R = Me			6a-c		7a-c
50 R = Bn		enone	catalyst	6:7 ratio	yield
		5a	(S)-Me-CBS	4:1	78%
		5a	(R)-Me-CBS	1:4	80%
		5b	(S)-Me-CBS	81:19	92%
		5b	(R)-Me-CBS	13:87	74%

enone **5a** was subjected to Luche reduction⁴¹ to afford a mixture of alcohols **9a** (Scheme 4). Enzymatic kinetic resolution of **9a** with vinyl acetate in the presence of lipase Novozyme 435 provided alcohol **7a** (dr > 95%, NMR) along with acetate **10a** (Scheme 4). Basic hydrolysis of the latter gave alcohol **6a** in 88% yield (dr > 95%, NMR, Scheme 4).

Subsequently, the transformation of allyl alcohol **6a** and **7a** into the corresponding allylamines was carried out. In the preliminary report,⁴² we demonstrated that such a transformation can be efficiently performed through a cyanate-to-isocyanate rearrangement reaction.⁴³ We also demonstrated that this procedure has several significant advantages over other known processes, for example, Overman rearrangement (vide infra).⁴⁴

Thus, allylic alcohols **6a** and **7a** were transformed into carbamates **11a** and **12a** by treatment with trichloroacetyl isocyanate (TCA-NCO) (Scheme 5). The resulting carbamates are stable and easier to handle than the corresponding trichloroacetimidates used in the Overman reaction.

Dehydration of 11a by treatment with trifluoroacetyl anhydride (TFAA) in the presence of Et₃N at 0 °C for 1 h provided allyl cyanate 13, which spontaneously rearranged to allyl isocyanate 14 (Scheme 6). This compound was not isolated, but directly trapped with MeOLi to provide stereospecifically carbamate 15 in 75% overall yield after 3 steps. Following the same one-pot, three-step protocol, carbamate 12a was transformed into cyanate 16, which rearranged to isocyanate 17. Direct treatment of 17 with MeOLi gave carbamate 18 in 60% yield after 3 steps. Mild and transition-metal-free reaction conditions, in contrast to Overman rearrangement, are additional advantages of the employed process. Moreover, treatment of the resulting allyl isocyanate (e.g., 14 or 17) with various nucleophiles opens a direct route to variously N-functionalized allylamines and, in consequence, differently protected amino acids (Table 1).

Finally, ozonolysis of **15** and **18** in the presence of 2.5 M methanolic NaOH (Marshall's procedure⁴⁵) gave methyl L-allothreonate **29** and methyl D-threonate **30**, respectively (Scheme 7). Similarly, allylamines **19–21** and **22–24** were converted into the corresponding amino esters **31–33** and **34–36** (Scheme 7).

Next, we prepared another two isomers of threonine, methyl L-threonate *ent*-34 and methyl D-*allo*-threonate *ent*-31, starting from methyl D-lactate and following the reaction sequence presented in Scheme 8.

The same approach was used to prepare β -phenyl-serines **38**, **40** and γ -phenyl-threonines **39** and **41**, starting from methyl L-mandelate and methyl L-phenyllactate, respectively (see Schemes 4, 5, and 7).

The above strategy is also applicable to the preparation of γ -hydroxy α -amino acids. This was exemplified by the synthesis of the corresponding amino acids **43a/45a** and **43b/45b** starting from commercially available methyl (*S*)-3-hydroxy-2-

Scheme 4



Scheme 5



methylpropanoate (Roche methyl ester) and methyl (R)-3-hydroxybutanoate, as shown in Scheme 9.

CONCLUSIONS

In conclusion, we described a new strategy for stereoselective preparation of all isomers of β -hydroxy α -amino acids. The developed procedure is based on enzymatic kinetic resolution and cyanate-to-isocyanate rearrangement as key steps. Proper choice of the starting hydroxyacid and the course of kinetic resolution enables the synthesis of all isomeric allyl diols. These, in turn, allow the stereoselective synthesis of all isomeric β -hydroxy α -amino acids, such as threonines, after rearrangement and further oxidation of the double bond. We have also presented an extension of this strategy that enables preparation

Scheme 6



OTPO

		1) TFAA, Et ₃ N, THF		
K,	O NH₂ O NH₂	2) nucleophile		ŇHR ²
entry	carbamate	nucleophile	R ²	yield [%] ^b
1	11a	MeOLi	Moc (15)	75
2	11a	BnOLi	Cbz (19)	76
3	11a	t-BuOLi	Boc (20)	84
4	11a	MeMgBr	Ac (21)	83
5	12a	MeOLi	Moc (18)	86
6	12a	BnOLi	Cbz (22)	70
7	12a	t-BuOLi	Boc (23)	76
8	12a	MeMgBr	Ac (24)	86
9	11b	BnOLi	Cbz (25)	77
10	12b	BnOLi	Cbz (26)	67
11	11c	BnOLi	Cbz (27)	82
12	12c	BnOLi	Cbz (28)	60

^{*a*}Reaction conditions: A cooled solution of carbamate (1 equiv) and Et_3N (6 equiv) in dry THF was treated with TFAA (2 equiv). After 1 h, a solution of nucleophile (ROLi or RMgBr) was added; ^{*b*}Isolated yield after 3 steps. TFAA = trifluoroacetyl anhydride

of γ -hydroxy α -amino acids. The incorporation of the amino functionality in the cyanate-to-isocyanate rearrangement step has several advantages. The reaction proceeds under mild conditions and does not require any transition-metal catalyst. The allyl carbamates, precursors of allyl isocyanates, are easily prepared and handled. As shown, the stereochemical course of sigmatropic rearrangement does not depend on the other



отро

Scheme 7

QTBS R ¹ NHR ² <u>O₃, NaOH</u> CH ₂ Cl ₂ , MeOH		S ,COO HR ²	Me	
		R^1	R^2	Yield [%]
15 R ¹ = Me, R ² = Moc	29	Me	Мос	85
19 R ¹ = Me, R ² = Cbz	31	Me	Cbz	71
20 R ¹ = Me, R ² = Boc	32	Me	Boc	92
21 R ¹ = Me, R ² = Ac	33	Me	Ac	82
25 R^1 = Ph, R^2 = Cbz	38	Ph	Cbz	86
26 R^1 = Bn, R^2 = Cbz	39	Bn	Cbz	89
OTBS R ¹ <u>i</u> NHR ² CH ₂ Cl ₂ , MeOH -78 °C	OTBS R ¹ COOMe			
		R ¹	R ²	Yield [%]
18 R ¹ = Me, R ² = Moc	30	Me	Мос	88
22 R^1 = Me, R^2 = Cbz	34	Me	Cbz	82
23 R^1 = Me, R^2 = Boc	35	Me	Boc	80
24 R^1 = Me, R^2 = Ac	36	Me	Ac	86
27 R^1 = Ph, R^2 = Cbz	40	Ph	Cbz	77
28 R' = Bn, R ² = Cbz	41	Bn	Cbz	82

stereogenic center present in the initial allyl carbamate. Thus, the effective chirality transfer allows for stereospecific preparation of either *erythro* or *threo* hydroxy allylamines. In addition, the allyl isocyanates, formed during the sigmatropic rearrangement, can be easily and directly functionalized by treatment with a nucleophile, which enables the preparation of differently protected allylamines.

EXPERIMENTAL SECTION

Methyl (5)-O-(t-Butyldimethylsilyl)-lactate (4a). Methyl Llactate (20 g, 19.4 mL, 169 mmol) and imidazole (22 g, 320 mmol) were dissolved in dry CH_2Cl_2 (350 mL). The solution was cooled to -15 °C and a solution of TBSCl (23 g, 155 mmol) in dry CH_2Cl_2 was added. The reaction mixture was stirred for 3 h at room temperature. After that time, water (200 mL) was added and the organic phase was

Scheme 8^a

separated and dried over anhydr. Na₂SO₄. After removal of the solvent, the residue was chromatographed on silica gel (5% AcOEt in cyclohexane) to afford 31.3 g (80%) of product 4a as a colorless oil. $[\alpha]_{D^2}^{22}$ –31.5 (*c* 1.4, CH₂Cl₂) [lit. –31.7 (*c* 0.66, CHCl₃)⁴⁶]; Spectral data:⁴⁷ ¹H NMR (400 MHz, CDCl₃) δ : 4.33 (m, 3H, CH₃O), 4.24–4.10 (m, 1H, CH₃CH), 1.39 (d, *J* 6.8 Hz, 3H, CH₃CH), 0.90 (s, 9H, *t*-BuSi), 0.10 (s, 3H, CH₃Si), 0.07 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 174.6, 68.4, 51.8, 25.7, 21.4, 18.3, –5.1, –5.3; HRMS (ESI-TOF) *m*/*z* calcd for C₁₁H₂₄O₃SiNa [M + Na⁺] 255.1392. Found 255.1390.

Ethyl (*R***)-O-(***t***-Butyldimethylsilyl)-lactate (***ent***-4a).** Prepared in the same manner as compound **4a**. $[\alpha]_D^{22}$ +30.1 (*c* 1.0, CH2Cl2); HRMS (ESI-TOF) m/z calcd for C₁₁H₂₄O₃SiNa [M + Na⁺] 255.1392. Found 255.1392.

Methyl (S)-2-(t-Butyldimethylsilyloxy)-2-phenylacetate (4b). To a solution of methyl (S)-(+)-mandelate (5 g, 30 mmol) and imidazole (4.1 g, 60 mmol) in dry CH₂Cl₂ (100 mL), a solution of TBSCl (4.3 g, 28.5 mmol) in CH2Cl2 (20 mL) was added. The reaction mixture was stirred overnight. Water (50 mL) was added, and the resulting mixture was stirred for 15 min. The organic layer was separated, and the aqueous layer was washed with CH_2Cl_2 (2 × 50 mL). The combined organic extracts were washed with brine (25 mL) and dried over anhydr. MgSO4, and solvent was removed under diminished pressure. The residue was chromatographed on silica gel (5% AcOEt in hexanes) to afford 7.3 g of product 4b (87%) as a colorless oil. $[\alpha]_{D}^{23}$ +52.8 (c 1.95, CH₂Cl₂) [lit.⁴⁸ +51.3 (c 1.03, CHCl₃)]; Spectral data:⁴⁸ ¹H NMR (500 MHz, CDCl₃) δ : 7.51–7.27 (m, 5H, Ph), 5.25 (s, 1H, PhCH), 3.69 (s, 3H, CH₃O), 0.92 (s, 9H, t-BuSi), 0.12 (s, 3H, CH₃Si), 0.04 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) *b*: 172.7, 139.3, 128.5, 128.2, 126.5, 74.6, 52.3, 25.8, 18.5, -4.9, -5.0; IR (ATR) v: 1761 cm⁻¹; HRMS (ESI-TOF) m/z calcd for $C_{15}H_{24}O_3SiNa [M + Na^+] 303.1392$. Found 303.1394.

Methyl (5)-2-((t-Butyldimethylsilyl)oxy)-3-phenylpropanoate (4c). Methyl L-phenyllactate (5.5 g, 30.5 mmol) and imidazole (2.7 g, 40 mmol) were dissolved in dry CH_2Cl_2 (150 mL). The solution was cooled to -15 °C, and a solution of TBSCl (4.5 g, 30 mmol) in dry CH_2Cl_2 (15 mL) was added. The reaction mixture was stirred for 3 h at room temperature. After that time, water (10 mL) was added, and the organic phase was separated and dried over anhydr. Na₂SO₄. After removal of solvent, the residue was chromatographed on silica gel (5% AcOEt in cyclohexane) to afford 5.7 g (65%) of product 4c as a colorless oil. $[\alpha]_D^{2h} - 32.8$ (c 2.05, CH_2Cl_2); ¹H



"Reagents and conditions: (a) vinyl acetate, Novozyme 435, MS 4 Å, pentane, rt (92% of *ent-6a* and 94% of 37); (b) i. TCA-NCO, CH_2Cl_2 , 0 °C; ii. aq. K_2CO_3 , MeOH, rt (91%); (c) i. TFAA, Et₃N, THF, -10 °C; ii. BnOH, LiHMDS, THF (80%); (d) O₃, NaOH, CH_2Cl_2 /MeOH, -78 °C (73%); (e) aq. K_2CO_3 , MeOH, rt (84%); (f) i. TCA-NCO, CH_2Cl_2 , 0 °C; ii. aq. K_2CO_3 , MeOH, rt (90%); (g) i. TFAA, Et₃N, THF, -10 °C; ii. BnOH, LiHMDS, THF (90%); (g) i. TFAA, Et₃N, THF, -10 °C; ii. BnOH, LiHMDS, THF (75%); (h) O₃, NaOH, CH_2Cl_2 /MeOH, -78 °C (83%). TCA-NCO = trichloroacetyl isocyanate, TFAA = trifluoroacetyl anhydride.

Scheme 9^{*a*}



^aReagents and conditions: (a) i. DIBAL-H, CH_2Cl_2 , -78 °C; ii. dimethyl(2-oxopropyl)phosphonate, NaH, THF, (77% for 4d, 75% for 4e); (b) $CeCl_3$ ·7H₂O, NaBH₄, CH_2Cl_2 /MeOH, rt (90% for 9d, 86% for 9e); (c) vinyl acetate, Novozyme 435, MS 4 Å, pentane (94% for 10d, 94% for 7d, 92% for 10e, and 96% for 7e); (d) i. TCA-NCO, CH_2Cl_2 , 0 °C; ii. aq. K_2CO_3 , MeOH, rt (79% for 12d, 84% for 12e); (e) i. TFAA, Et₃N, THF, -10 °C; ii. BnOH, LiHMDS, THF (87% for 42a, 78% for 42b); (f) O₃, NaOH, CH_2Cl_2 /MeOH, -78 °C (87% for 43a, 60% for 43b); (g) aq. K_2CO_3 , MeOH, rt (85% for 6d, 65% for 6e); (h) i. TCA-NCO, CH_2Cl_2 , 0 °C; ii. aq. K_2CO_3 , MeOH, rt (97% for 11d, 74% for 11e); (i) i. TFAA, Et₃N, THF, -10 °C; ii. BnOH, LiHMDS, THF (88% for 44a, 87% for 44b); (j) O₃, NaOH, CH_2Cl_2 /MeOH, -78 °C (87% for 45a, 93% for 45b); TCA-NCO = trichloroacetyl isocyanate, TFAA = trifluoroacetyl anhydride.

NMR (500 MHz, CDCl₃) δ : 7.35–7.12 (m, 5H, Ph), 4.34 (dd, *J* 9.0, 3.9 Hz, 1H, CHCOOMe), 3.72 (s, 3H, CH₃O), 3.07 (dd, *J* 13.4, 3.9 Hz, 1H, PhCHH), 2.88 (dd, *J* 13.4, 9.0 Hz, 1H, PhCHH), 0.79 (s, 9H, *t*-BuSi), -0.12 (s, 3H, CH₃Si), -0.21 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 173.7, 137.6, 129.9, 128.3, 126.7, 74.0, 41.8, 27.1, 25.7, 18.4, -5.4, -5.5; IR (film) v: 1762 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₆H₂₆O₃SiLi [M + Li⁺] 301.1811. Found 301.1804.

Methyl (S)-3-((t-Butyldimethylsilyl)oxy)-2-methyl**propanoate** (4d). Methyl (S)-(+)-3-hydroxy-2-methylpropionate (5.0 g, 42.3 mmol) and imidazole (3.4 g, 50.0 mmol) were dissolved in dry CH_2Cl_2 (150 mL). The solution was cooled to -15 °C, and a solution of TBSCl (6.45 g, 43.0 mmol) in dry CH₂Cl₂ (20 mL) was added. The reaction mixture was stirred for 3 h at room temperature. After that time, water (100 mL) was added, and the organic phase was separated and dried over anhydr. Na2SO4. After removal of solvent, the residue was chromatographed on silica gel (10% AcOEt in cyclohexane) to afford 8.6 g (88%) of product 4d as a colorless oil. $[\alpha]_{D}^{24}$ +20.3 (c 1.3 CH₂Cl₂) [lit.⁴⁹ +18.8 (c 1, CHCl₃)]; ¹H NMR (500 MHz, CDCl₃) δ: 3.77 (dd, J 9.7, 6.9 Hz, 1H, TBSOCHH), 3.67 (s, 3H, CH₃O), 3.65 (dd, J 9.7, 6.1 Hz, 1H, TBSOCHH), 2.70-2.59 (m, 1H, CH₃CH), 1.14 (d, J 7.0 Hz, 3H, CH₃CH), 0.87 (s, 9H, t-BuSi), 0.07-0.01 (m, 6H, 2× CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 175.4, 65.2, 51.5, 42.5, 25.7, 18.2, 13.4, -5.5; IR (film) v: 1743, 1256, 1099, 838, 777 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₁₁H₂₄O₃SiNa $[M + Na^+]$ 255.1392. Found 255.1388.

Methyl (*R*)-3-((*t*-Butyldimethylsilyl)oxy)butanoate (4e). Methyl (*R*)-(-)-3-hydroxybutyrate (6.0 g, 50.79 mmol) and imidazole (5.2 g, 76.38 mmol) were dissolved in dry CH₂Cl₂ (200 mL). The solution was cooled to -15 °C, and a solution of TBSCl (7.6 g, 50.79 mmol) in dry CH₂Cl₂ (25 mL) was added. The reaction mixture was stirred for 3 h at room temperature. After that time, water (100 mL) was added, and the organic phase was separated and dried over anhydr. Na₂SO₄. After removal of the solvent, the residue was chromato-graphed on silica gel (10% AcOEt in cyclohexane) to afford 4.27 g (63%) of product as a colorless oil. [α]₂^{D4} -32.5 (*c* 1.34, CH₂Cl₂) [lit.⁵⁰ -32 (*c* 1.3, CHCl₃)]; Spectral data:^{47 1}H NMR (500 MHz, CDCl₃) δ : 4.37–4.19 (m, 1H, CH₃CH), 3.66 (s, 3H, CH₃O), 2.48 (dd, J 14.5, 7.7 Hz, 1H, CHHCOOMe), 2.37 (dd, J 14.5, 5.3 Hz, 1H, CHHCOOMe), 1.19 (d, J 6.1 Hz, 3H, CH₃CH), 0.86 (s, 9H, *t*-BuSi), 0.06 (s, 3H, CH₃Si), 0.04 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ 172.2, 66.0, 51.5, 44.9, 25.8, 24.1, 18.1, -4.4, -4.9; IR (film) ν : 2955, 2930, 1743, 1256, 1085, 837, 776 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₁H₂₄O₃SiNa [M + Na⁺] 255.1392. Found 255.1392.

(S,E)-5-((t-Butyldimethylsilyl)oxy)hex-3-en-2-one (5a). To a solution of ester 4a (10 g, 43 mmol) in dry CH₂Cl₂ (200 mL) at -78 °C, a 1 M solution of DIBAL-H in hexanes (43 mL, 43 mmol) was added over 1 h (syringe pump). In a second flask, to a suspension of NaH (2.24 g, 60% disp. in mineral oil, 56 mmol) in dry THF (200 mL), dimethyl (2-oxopropyl)phosphonate (9.3 g, 7.7 mL, 56 mmol) was slowly added, and the mixture was stirred at room temperature for 1 h to produce the HWE reagent solution. When reduction was completed (TLC control, 20% AcOEt in hexanes), a solution of HWE reagent was cannulated into the aldehyde solution at -78 °C. The resulting mixture was allowed to warm up slowly to room temperature and was stirred for 3 h. Sat. aq. Rochelle salt (100 mL) was carefully added to the mixture, and stirring was continued for 30 min. The mixture was diluted with Et₂O (300 mL). The organic layer was separated, and the aqueous solution was extracted with Et_2O (4 \times 50 mL). The combined organic extracts were dried over Na2SO4, and solvents were removed under reduced pressure. The residue was purified by chromatography on silica gel (10% AcOEt/hexanes) to give 7.95 g of 5a (80%) as a colorless oil. $[\alpha]_{D}^{22}$ +8.8 (c 2.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 6.73 (dd, J 15.8, 3.9 Hz, 1H, CH= CHCOMe), 6.22 (d, J 15.8 Hz, 1H, CH=CHCOMe), 4.52-4.41 (m, 1H, CHMe), 2.26 (m, 3H, CH₃CO), 1.27 (d, J 6.4 Hz, 3H, CH₃CH), 0.91 (s, 9H, t-BuSi), 0.07 (s, 3H, CH₃Si), 0.06 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 198.9, 150.8, 128.3, 67.9, 27.4, 25.9, 23.8, 18.4, -4.7; IR (film) ν : 1681 cm⁻¹; HRMS (ESI-TOF) m/z calcd for $C_{12}H_{24}O_2SiNa [M + Na^+] 251.1443$. Found 251.1438.

(*R*,*E*)-5-((*t*-Butyldimethylsilyl)oxy)hex-3-en-2-one (*ent*-5a). Prepared in the same manner as compound 5a. $[\alpha]_D^{22}$ -9.1 (*c* 1.5, CHCl₃); HRMS (ESI-TOF) m/z calcd for C₁₂H₂₄O₂SiNa [M + Na⁺] 251.1443. Found 251.1441.

(*R*,*E*)-5-((*t*-Butyldimethylsilyl)oxy)-5-phenylpent-3-en-2-one (5b). Compound 5b was prepared in the same manner as compound 5a. Yield 86%; colorless oil; $[\alpha]_{25}^{D5}$ +46.2 (*c* 1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.40–7.23 (m, 5H, Ph), 6.77 (dd, *J* 15.8, 4.8 Hz, 1H, CH=CHCOMe), 6.34 (dd, *J* 15.8, 1.5 Hz, 1H, CH=CHCOMe),

5.39–5.29 (m, 1H, CHPh), 2.23 (s, 3H, CH₃CO), 0.91 (s, 9H, *t*-BuSi), 0.07 (s, 3H, CH₃Si), -0.04 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 198.9, 149.3, 141.8, 128.7, 128.2, 127.9, 126.3, 74.5, 27.2, 25.9, 18.4, -4.72, -4.74; IR (film) ν : 1678, 1254, 838 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₇H₂₇O₂Si [M + H⁺] 291.1780. Found 291.1777.

(*S,E*)-5-(*t*-Butyldimethylsilyloxy)-6-phenylhex-3-en-2-one (5c). Compound 5c was prepared in the same manner as compound 5a. Purification by chromatography on silica gel (10% AcOEt/ hexanes). Yield 3.29 g (70%) starting from 4.53 g (15.38 mmol) of ester 4c; colorless oil; $[\alpha]_D^{23} + 4.2$ (*c* 2.4, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.36–7.10 (m, 5H), 6.75 (dd, *J* 15.9, 4.9 Hz, 1H, CH= CH-COMe), 6.20 (dd, *J* 15.9, 1.5 Hz, 1H, CH=CH–COMe), 4.55– 4.39 (m, 1H, CH₃CO), 2.89–2.76 (m, 2H, PhCH₂), 2.23 (s, 3H, CH₃CO), 0.86 (s, 9H, *t*-BuSi), -0.08 (s, 3H, CH₃Si), -0.20 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 198.6, 149.2, 137.6, 129.9, 129.3, 128.4, 126.7, 73.4, 44.6, 27.4, 25.9, 18.3, -4.7, -5.2; IR (film) *v*: 1680, 1254, 1118 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₈H₂₈-O₂SiNa [M + Na⁺] 327.1756. Found 327.1753.

(*R*,*E*)-6-(*t*-Butyldimethylsilyloxy)-5-methylhex-3-en-2-one (5d). Compound 5d was prepared in the same manner as compound 5a. Purification by chromatography on silica gel (10% AcOEt/hexanes). Yield 4.1 g (77%) starting from 5 g (21.6 mmol) of ester 4d; colorless oil; $[\alpha]_D^{23}$ +25.3 (*c* 2.05, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 6.78 (dd, *J* 16.2, 7.1 Hz, 1H, CH=CHCOMe), 6.08 (dd, *J* 16.2, 1.2 Hz, 1H, CH=CHCOMe), 3.57–3.53 (m, 2H, CH₂OTBS), 2.56–2.47 (m, 1H, -CHCH₃), 2.24 (s, 3H, CH₃CO), 1.06 (d, *J* 6.8 Hz, 3H, CH₃CH), 0.89 (s, 9H, *t*-BuSi), 0.03 (s, 6H, 2 × CH₃Si); ¹³C NMR (125 MHz, CDCl₃) δ : 198.7, 150.6, 130.7, 66.9, 39.3, 26.7, 25.8, 25.7, 15.5, -5.4; IR (film) *v*: 1679, 1254, 1098 cm⁻¹; HRMS (ESI-TOF): *m*/*z* calcd for C₁₃H₂₆O₂SiNa [M + Na⁺] 265.1600. Found 265.1599.

(*R*,*E*)-6-((*t*-Butyldimethylsilyl)oxy)hept-3-en-2-one (5e). Compound 5e was prepared in the same manner as compound 5a. Purification by chromatography on silica gel (10% AcOEt/hexanes). Yield 3.02 g (75%) starting from 3.8 g (16.35 mmol) of ester 4e; colorless oil. $[\alpha]_{D}^{22}$ -14.9 (*c* 1.15, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 6.80 (dt, *J* 16.0, 7.4 Hz, 1H, CH=CHCO), 6.07 (d, *J* 16.0 Hz, 1H, CH=CHCO), 3.94 (hept, *J* 6.0 Hz, 1H, CH₃CH), 2.38–2.28 (m, 2H, CH₂CH=CH), 2.23 (s, 3H, CH₃CO), 1.16 (d, *J* 6.1 Hz, 3H, CH₃CH), 0.87 (s, 9H, *t*-BuSI), 0.05 (s, 3H, CH₃Si), 0.03 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 198.4, 145.2, 133.2, 67.6, 42.6, 26.6, 25.7, 23.8, 18.0, -4.5, -4.8; IR (film) *v*: 1742, 1677, 1254, 836, 775 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₃H₂₆O₂SiNa [M + Na⁺] 265.1600. Found 265.1591.

(55,E)-5-(t-Butyldimethylsilyloxy)hex-3-en-2-ol (9a). To a suspension of enone 5a (5 g, 21.9 mmol) and CeCl₃·7H₂O (9.86 g, 26 mmol) in CH₂Cl₂-MeOH (3:1 v/v, 100 mL), NaBH₄ (910 mg, 24.1 mmol) was added portionwise. After stirring at ambient temperature for 3 h, the reaction mixture was partitioned between CH₂Cl₂ (120 mL) and sat. aq. sodium potassium tartrate (50 mL). The organic layer was separated, and the aqueous layer was washed with CH₂Cl₂ (4 × 50 mL). The combined organic solutions were dried over anhydr. Na₂SO₄, and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel (20% AcOEt/hexanes) to afford 4.59 g (91%) of a mixture of alcohols 9a. HRMS (ESI-TOF) *m*/*z* calcd for C₁₂H₂₆O₂SiNa [M + Na⁺] 253.1600. Found 253.1596.

(5*R*,*E*)-5-(*t*-Butyldimethylsilyloxy)hex-3-en-2-ol (5-*epi*-9a). Prepared in the same manner as compound 9a. Yield 89% (NMR); HRMS (ESI-TOF) m/z calcd for C₁₂H₂₆O₂SiNa [M + Na⁺] 253.1600. Found 253.1598.

(5*R*,*E*)-5-((*t*-Butyldimethylsilyl)oxy)-5-phenylpent-3-en-2-ol (9b). Prepared in the same manner as compound 9a and was used directly in the next step. Yield 91%; HPLC: Chiralpak IB, 5% *i*-PrOH/ hexanes, flow 1 mL/min, R_t 7.1 min (2*R*,5*R*) and 8.7 min (2*S*,5*R*).

(*S,E*)-5-(*t*-Butyldimethylsilyloxy)-6-phenylhex-3-en-2-ol (9c). Prepared in the same manner as compound 9a. Purification by chromatography on silica gel (10% AcOEt/hexanes). Yield 95%. (5*R*,*E*)-6-(*t*-Butyldimethylsilyloxy)-5-methylhex-3-en-2-ol (9d). Prepared in the same manner as compound 9a. Purification by chromatography on silica gel (10% AcOEt/hexanes); Yield 90%.

(6R,E)-6-((t-Butyldimethylsilyl)oxy)hept-3-en-2-ol (9e). Prepared in the same manner as compound 9a and used without further purification. Yield 86%.

Enzymatic Kinetic Resolution of Alcohols 9a. A suspension of alcohols **9a** (4.06 g, 17.2 mmol), Novozyme 435 (100 mg), 4 Å molecular sieves (500 mg), and vinyl acetate (25 mL) in pentane (30 mL) was stirred overnight. The progress of the reaction was followed by ¹H NMR. The reaction mixture was filtered through Celite, and the solvent was removed under diminished pressure. The residue was chromatographed on silica gel (15% AcOEt/hexanes) to afford 2.28 g of acetate **10a** (96%) and 1.93 g of alcohol **7a** (94%).

(2*R*,5*S*,*E*)-5-(*t*-Butyldimethylsilyloxy)hex-3-en-2-yl Acetate (10a). ¹H NMR (500 MHz, CDCl₃) δ : 5.69 (dd, *J* 15.5, 5.1 Hz, 1H, CH=CH), 5.59 (ddd, *J* 15.5, 6.2, 1.1 Hz, 1H, CH=CH), 5.38– 5.28 (m, 1H, CHOAc), 4.34–4.23 (m, 1H, CHOTBS), 2.02 (s, 3H, CH₃CO), 1.29 (d, *J* 6.5 Hz, 3H, CH₃), 1.19 (d, *J* 6.4 Hz, 3H, CH₃), 0.88 (s, 9H, *t*-BuSi), 0.04 (s, 3H, CH₃Si), 0.03 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 170.4, 136.7, 128.1, 70.6, 68.6, 26.0, 24.4, 21.5, 20.4, 18.4, -4.5, -4.6; IR (film) *v*: 1739, 1241, 1101, 836 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₄H₂₈O₃SiNa [M + Na⁺] 295.1705. Found 295.1703.

(25,55,*E*)-5-(*t*-Butyldimethylsilyloxy)hex-3-en-2-ol (7a). *dr* > 95:5 (NMR); $[\alpha]_D^{23}$ -3.5 (*c* 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.70-5.60 (m, 2H, CH=CH), 4.34-4.25 (m, 2H, 2 × CH), 1.25 (d, *J* 6.4 Hz, 3H, CH₃), 1.20 (d, *J* 6.4 Hz, 3H, CH₃), 0.89 (s, 9H, *t*-BuSi), 0.05 (s, 3H, CH₃Si), 0.05 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ; 134.7, 132.6, 68.7, 68.4, 26.0, 24.5, 23.5, 18.4, -4.4, -4.6; IR (film) *v*: 3348, 1254, 1084, 1058, 835 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₂H₂₆O₂SiNa [M + Na⁺] 253.1600. Found 253.1593.

(2*S*,5*R*,*E*)-5-(*t*-Butyldimethylsilyloxy)hex-3-en-2-ol (*ent*-6a). Yield 1.1 g (47%); $[\alpha]_D^{23}$ -31.6 (*c* 0.9, CH₂Cl₂); HRMS (ESI-TOF) *m*/*z* calcd for C₁₂H₂₆O₂SiNa [M + Na⁺]2S3.1600. Found 2S3.1597.

Enzymatic Kinetic Resolution of Alcohols 9b. A suspension of alcohols **9b** (1.96 g, 6.7 mmol), Novozyme 435 (100 mg), 4 Å molecular sieves (500 mg), and vinyl acetate (25 mL) in pentane (30 mL) was stirred overnight. The progress of the reaction was followed by ¹H NMR. The reaction mixture was filtered through a Celite pad, and solvents were removed under diminished pressure. The residue was chromatographed on silica gel (10% AcOEt/hexanes) to afford 1.07 g of acetate **10b** (96%) and 0.98 g of alcohol **7b** (96%).

(2 \tilde{R} ,5R,E)-5-((*t*-Butyldimethylsilyl)oxy)-5-phenylpent-3-en-2yl Acetate (10b). Colorless oil; $[\alpha]_{D^2}^{2D}$ +64.9 (*c* 1.6, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 7.30–7.16 (m, 5H, Ph), 5.77–5.66 (m, 2H, CH=CH), 5.34–5.28 (m, 1H, CH₃CH), 5.13 (d, *J* 4.5 Hz, 1H, PhCH), 1.97 (s, 3H, CH₃CO), 1.25 (d, *J* 6.5 Hz, 3H, CH₃CH), 0.87 (s, 9H, *t*-BuSi), 0.02 (s, 3H, CH₃Si), -0.05 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ: 170.4, 143.6, 135.3, 128.9, 128.4, 127.3, 126.2, 74.9, 70.4, 26.0, 21.5, 20.3, 18.5, -4.4, -4.7; IR (film) *v*: 1740, 1241, 837 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₉H₃₀O₃SiNa [M + Na⁺] 357.1862. Found 357.1863.

(25,5*R*,*E*)-5-((*t*-Butyldimethylsilyl)oxy)-5-phenylpent-3-en-2ol (7b). Colorless oil; $[\alpha]_{D}^{22}$ +21.7 (*c* 1.49, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.26–7.14 (m, 5H, Ph), 5.78–5.64 (m, 2H, CH= CH), 5.12 (d, *J* 4.8 Hz, 1H, PhCH), 4.31–4.20 (m, 1H, CH₃CH), 1.20 (d, *J* 6.4 Hz, 3H, CH₃CH), 0.86 (s, 9H, *t*-BuSi), 0.01 (s, 3H, CH₃Si), -0.06 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 143.9, 133.6, 133.5, 128.35, 127.2, 126.1, 75.0, 68.3, 26.0, 23.3, 18.5, -4.4, -4.6; IR (film) ν : 3348, 1255, 836 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₇H₂₈O₂SiNa [M + Na⁺] 315.1756. Found 315.1760.

Enzymatic Kinetic Resolution of Alcohols 9c. A suspension of alcohols **9c** (2.8, 9.14 mmol), Novozyme 435 (135 mg), 4 Å molecular sieves (680 mg), and vinyl acetate (14 mL) in pentane (40 mL) was stirred overnight. The progress of the reaction was followed by ¹H NMR. The reaction mixture was filtered through a Celite pad, and solvents were removed under diminished pressure. The residue was

chromatographed on silica gel ($10\% \rightarrow 20\%$ AcOEt/hexanes) to afford 1.33 g of acetate **10c** (84%) and 1.28 g of alcohol 7c (92%).

(2 \bar{R} ,5*S*,*E*)-5-(*t*-Butyldimethylsilyloxy)-6-phenylhex-3-en-2-yl Acetate (10c). Colorless oil; ¹H NMR (500 MHz, CDCl₃) δ: 7.30– 7.09 (m, 5H, Ph), 5.71 (dd, *J* 15.4, 5.7 Hz, 1H, CH=CH), 5.56 (ddd, *J* 15.5, 6.3, 0.8 Hz, 1H, CH=CH), 5.36–5.29 (m, 1H, CHO–), 4.26 (q, *J* 6.1 Hz, 1H, CHO–), 2.74 (d, *J* 6.5 Hz, 2H, CH₂Ph), 2.02 (s, 3H, CH₃CO), 1.27 (d, *J* 6.5 Hz, 3H, CHCH₃), 0.84 (d, *J* 9.4 Hz, 9H, *t*-BuSi), -0.12 (s, 3H, CH₃Si), -0.21 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ: 170.6, 138.6, 134.9, 130.1, 129.4, 128.2, 126.3, 74.2, 70.5, 45.2, 25.9, 21.5, 20.4, 18.34, -4.6, -5.1; HRMS (ESI-TOF) *m/z* calcd for C₂₀H₃₂O₃SiNa [M + Na⁺] 371.2018. Found 371.2012.

(25,55,*E*)-5-(*t*-Butyldimethylsilyloxy)-6-phenylhex-3-en-2-ol (7c). Colorless oil; $[\alpha]_D^{23} - 9.7$ (*c* 1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.34–7.04 (m, 5H, Ph), 5.73–5.56 (m, 2H, CH=CH), 4.34–4.20 (m, 2H, 2× CHO–), 2.76 (d, *J* 6.5 Hz, 2H, CH₂Ph), 1.22 (d, *J* 6.4 Hz, 3H, CH₃CH), 0.84 (s, 9H, *t*-BuSi), -0.09 (s, 3H, CH₃Si), -0.20 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 138.6, 133.8, 132.8, 129.9, 128.0, 126.1, 74.1, 68.3, 45.2, 25.8, 23.3, 18.2, -4.6, -5.2; IR (film) *v*: 3353, 1254, 1078, 835 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₈H₃₀O₂SiNa [M + Na⁺] 329.1913. Found 329.1908.

Enzymatic Kinetic Resolution of Alcohols 9d. A suspension of alcohols **9d** (2.45 g, 10 mmol), Novozyme 435 (150 mg), 4 Å molecular sieves (750 mg), and vinyl acetate (11 mL) in pentane (50 mL) was stirred overnight. The progress of the reaction was followed by ¹H NMR. The reaction mixture was filtered through a Celite pad, and solvents were removed under diminished pressure. The residue was chromatographed on silica gel (10% \rightarrow 20% AcOEt/hexanes) to afford 1.36 g of acetate **10d** (94%) and 1.15 g of alcohol **7d** (94%, *dr* 95:5, NMR).

(2*R*,5*R*,*E*)-6-(*tert*-Butyldimethylsilyloxy)-5-methylhex-3-en-2yl Acetate (10d). [α]_D²³ +56.2 (*c* 1.9, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.64 (dd, *J* 15.6, 6.9 Hz, 1H, CH=CH), 5.49 (dd, *J* 15.6, 6.5 Hz, 1H, CH=CH), 5.32 (p, *J* 6.4 Hz, 1H, CHOAc), 3.47 (dd, *J* 9.7, 6.4 Hz, 1H, CHHOTBS), 3.41 (dd, *J* 9.7, 6.7 Hz, 1H, CHHOTBS), 2.37–2.25 (m, 1H, CHCH₃), 2.03 (s, 3H, CH₃CO), 1.29 (d, *J* 6.4 Hz, 3H, CH₃CHOAc), 0.98 (d, *J* 6.8 Hz, 3H, CH₃CH), 0.89 (s, 9H, *t*-BuSi), 0.03 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ 170.5, 135.6, 129.3, 71.2, 67.9, 39.0, 26.1, 21.5, 20.5, 18.5, 16.3, -5.2, -5.2; HRMS (ESI-TOF) *m*/*z* calcd for C₁₅H₃₀O₃SiNa [M + Na⁺] 309.1862. Found 309.1858.

(25,5*R*,*E*)-6-(*t*-Butyldimethylsilyloxy)-5-methylhex-3-en-2-ol (7d). Colorless oil; $[\alpha]_D^{25}$ +4.5 (*c* 2.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 5.64–5.47 (m, 2H, CH=CH), 4.32–4.22 (m, 1H, CHOH), 3.48 (dd, *J* 9.7, 6.3 Hz, 1H, CHHOTBS), 3.40 (dd, *J* 9.7, 6.8 Hz, 1H, CHHOTBS), 2.37–2.21 (m, 1H, CHCH₃), 1.26 (d, *J* 6.3 Hz, 3H, CH₃CHOH), 0.99 (d, *J* 6.8 Hz, 3H, CH₃CH), 0.89 (s, 9H, *t*-BuSi), 0.04 (s, 6H, 2 × CH₃Si); ¹³C NMR (125 MHz, CDCl₃) δ : 134.1, 133.6, 69.2, 68.1, 39.0, 26.1, 23.6, 18.5, 16.6, -5.17, -5.19; IR (film) ν : 3350, 1255, 1120, 1091, 837 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₃H₂₈O₂SiNa [M + Na⁺] 267.1756. Found 267.1756.

Enzymatic Kinetic Resolution of Alcohols 9e. A suspension of alcohols **9e** (2.4 g,), Novozyme 435 (146 mg), 4 Å molecular sieves (730 mg), and vinyl acetate (23 mL) in pentane (45 mL) was stirred overnight. The progress of the reaction was followed by ¹H NMR. The reaction mixture was filtered through a Celite pad, and solvents were removed under diminished pressure. The residue was chromatographed on silica gel (10% to 20% AcOEt/hexanes) to afford 1.28 g of acetate **10e** (92%) and 1.16 g of alcohol **7e** (96%, *dr* 94:6, NMR).

(2*R*,6*R*,*E*)-6-((*t*-Butyldimethylsilyl)oxy)hept-3-en-2-yl Acetate (10e). Colorless oil; $[\alpha]_{D^2}^{D^2}$ +21.7 (*c* 2.2, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 5.74–5.62 (m, 1H, CH=CH), 5.47 (ddt, *J* 15.4, 6.6, 1.2 Hz, 1H, CH=CH), 5.35–5.26 (m, 1H, CH), 3.86–3.76 (m, 1H, CH), 2.20–2.06 (m, 2H, CH₂), 2.02 (s, 3H, CH₃CO), 1.28 (d, *J* 6.5 Hz, 3H, CH₃), 1.10 (d, *J* 6.1 Hz, 3H, CH₃), 0.87 (s, 9H, *t*-BuSi), 0.03 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 170.3, 131.5, 129.9, 70.9, 68.3, 42.5, 25.8, 25.7, 23.6, 21.4, 20.2, 18.1, -4.5, -4.8; HRMS (ESI-TOF) *m*/*z* calcd for C₁₅H₃₀O₃SiNa [M + Na⁺] 309.1862. Found 309.1862. (25,6*R*,*E*)-6-((*t*-Butyldimethylsilyl)oxy)hept-3-en-2-ol (7e). Colorless oil; $[\alpha]_{D}^{2D}$ -13.7 (*c* 2.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 5.68–5.59 (m, 1H, CH=CH), 5.54 (dd, *J* 15.4, 6.4 Hz, 1H, CH=CH), 4.32–4.21 (m, 1H, CH), 3.86–3.77 (m, 1H, CH), 2.22–2.07 (m, 2H, CH₂), 1.25 (d, *J* 6.4 Hz, 3H, CH₃), 1.12 (d, *J* 6.1 Hz, 3H), 0.88 (s, 9H, *t*-BuSi), 0.045 (s, 3H, CH₃Si), 0.042 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ 136.3, 127.6, 68.9, 68.5, 42.4, 25.8, 23.5, 23.3, 18.1, -4.5, -4.7; IR (film) *v*: 3345, 1256, 1077, 1060, 833 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₃H₂₈O₂SiNa [M + Na⁺] 267.1756. Found 267.1754.

(2R,5S,E)-5-(t-Butyldimethylsilyloxy)hex-3-en-2-ol (6a). To a solution of acetate 10a (2.15 g, 7.89 mmol) in MeOH (12 mL), a solution of $K_2 \text{CO}_3$ (2.18 g, 15.77 mmol) in H_2O (5 mL) was added, and the resulting mixture was kept at ambient temperature. The progress of hydrolysis was followed by TLC (20% AcOEt/hexanes). After stirring overnight, MeOH was removed under diminished pressure and the aqueous solution was extracted with CH_2Cl_2 (3 × 50 mL). The combined organic extracts were dried over anhydr. Na₂SO₄, and the solvent was removed under diminished pressure. The residue was chromatographed on silica gel (10% \rightarrow 20% AcOEt/hexanes) to afford 1.61 g of alcohol **6a** (88%) as a colorless oil. $\left[\alpha\right]_{D}^{23}$ +32 (c 1.1, CH_2Cl_2 ; ¹H NMR (500 MHz, CDCl₃) δ : 5.74–5.57 (m, 2H, CH= CH), 4.40-4.22 (m, 2H, CH₃CHOTBS, CH₃CHOH), 1.27 (d, J 6.4 Hz, 3H, CH₃CH), 1.21 (d, J 6.4 Hz, 3H, CH₃CH), 0.90 (s, 9H, t-BuSi), 0.06 (s, 3H, CH₃Si), 0.05 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) *δ* 134.8, 132.6, 68.7, 68.6, 26.1, 24.5, 23.5, 18.4, -4.4, -4.6; IR (film) v: 3342, 1255, 1080, 1062, 834 cm⁻¹; HRMS (ESI-TOF) m/zcalcd for C₁₂H₂₆O₂SiNa [M + Na⁺] 253.1600. Found 253.1591.

(2*R*,5*R*,*E*)-5-(*t*-**Butyldimethylsilyloxy)hex-3-en-2-ol** (*ent-*7**a**). Yield 752 mg (84%); colorless oil; $[\alpha]_D^{23}$ +3.7 (*c* 1.2, CHCl₃); HRMS (ESI-TOF) *m*/*z* calcd for C₁₂H₂₆O₂SiNa [M + Na⁺] 253.1600. Found 253.1598.

(2*R*,5*R*,*E*)-5-((*t*-Butyldimethylsilyl)oxy)-5-phenylpent-3-en-2ol (6b). Prepared in the same manner as compound 6a. Purification by chromatography on silica gel (15% AcOEt/hexanes). Yield 0.76 g (82%) starting from 1.07 g (3.21 mmol) of acetate 10b; colorless oil; *dr* 95:5 (NMR); $[\alpha]_D^{23}$ +21.6 (*c* 1.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 7.27–7.14 (m, 5H, Ph), 5.75–5.62 (m, 2H, CH=CH), 5.12 (d, *J* 5.0 Hz, 1H, PhCH), 4.28–4.20 (m, 1H, CH₃CH), 1.21 (d, *J* 6.4 Hz, 3H, CH₃CH), 0.85 (s, 9H, *t*-BuSi), 0.00 (s, 3H, CH₃Si), -0.06 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ: 143.9, 133.7, 133.5, 128.4, 127.2, 126.1, 75.1, 68.4, 26.0, 23.3, 18.5, -4.4, -4.6; IR (film) *v*: 3348, 1255, 836 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₇H₂₈-O₂SiNa [M + Na⁺] 315.1756. Found 315.1751.

(2*R*,5*S*,*E*)-5-((*t*-Butyldimethylsilyl)oxy)-6-phenylhex-3-en-2ol (6c). Prepared in the same manner as compound 6a. Purification by chromatography on silica gel (10% AcOEt/hexanes). Yield 0.98 g (84%) starting from 1.33 g (3.82 mmol) of acetate **10c**; as colorless oil; $[\alpha]_{D}^{23}$ +0.6 (*c* 1.4, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 7.29– 7.14 (m, 5H, Ph), 5.67 (dd, *J* 15.8, 5.4 Hz, 1H, CH=CH), 5.61 (dd, *J* 15.8, 5.6 Hz, 1H, CH=CH), 4.34–4.22 (m, 2H, CH₃CH, BnCH), 2.76 (d, *J* 6.5 Hz, 2H, PhCH₂CH), 1.23 (d, *J* 6.4 Hz, 3H, CH₃CH), 0.83 (s, 9H, *t*-BuSi), -0.10 (s, 3H, CH₃Si), -0.21 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ: 138.7, 134.0, 132.9, 130.1, 128.2, 126.3, 74.3, 68.5, 45.3, 26.0, 23.4, 18.3, -4.5, -5.1; IR (film) *v*: 3349, 1254, 1077, 855 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₈H₃₀O₂SiNa [M + Na⁺] 329.1913. Found 329.1910.

(2*R*,5*R*,*E*)-6-((*t*-Butyldimethylsilyl)oxy)-5-methylhex-3-en-2ol (6d). Prepared in the same manner as compound 6a. Purification by chromatography on silica gel (10% AcOEt/hexanes). Yield 1.08 g (85%) starting from 1.4 g (4.88 mmol) of acetate 10d; colorless oil; *dr* 94:6 (NMR); $[\alpha]_D^{23}$ +18 (*c* 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 5.59 (dd, *J* 15.6, 6.0 Hz, 1H, CH=CH), 5.54 (dd, *J* 15.6, 5.6 Hz, 1H, CH=CH), 4.30–4.22 (m, 1H, CH=CHCHOH), 3.49 (dd, *J* 9.7, 6.2 Hz, 1H, TBSOCHH), 3.40 (dd, *J* 9.7, 6.9 Hz, 1H, TBSOCHH), 2.36–2.27 (m, 1H, CHCH₃), 1.26 (d, *J* 6.3 Hz, 3H, CH₃), 0.99 (d, *J* 6.8 Hz, 3H, CH), 0.89 (s, 9H, *t*-Bu) 0.04 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ 134.0, 133.5, 69.1, 68.1, 38.9, 26.1, 23.5, 18.5, 16.6, -5.2; IR (film) *v*: 3348, 1471, 1255, 1089, 838, 775 cm⁻¹;

HRMS (TOF-ESI) m/z calcd for C₁₃H₂₈O₂SiNa [M + Na⁺] 267.1756. Found 267.1748.

(2*R*,6*R*,*E*)-6-((*t*-Butyldimethylsilyl)oxy)hept-3-en-2-ol (6e). Prepared in the same manner as compound 6a. Purification by chromatography on silica gel (10% AcOEt/hexanes). Yield 808 mg (65%) starting from 1.45 g (5.1 mmol) of acetate 10e ; colorless oil; *dr* 95:5 (NMR); $[\alpha]_{22}^{22}$ +1.4 (*c* 0.7, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 5.67–5.58 (m, 1H, CH=CH), 5.53 (dd, *J* 15.4, 6.4 Hz, 1H, CH= CH), 4.30–4.19 (m, 1H, CH), 3.81 (h, *J* 6.1 Hz, 1H, Ci), 2.20–2.06 (m, 2H, CH₂), 1.24 (d, *J* 6.3 Hz, 3H, CH₃), 1.10 (d, *J* 6.1 Hz, 3H, CH₃), 0.86 (s, 9H, *t*-BuSi), 0.03 (s, 3H, CH₃Si), 0.02 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 136.3, 127.6, 68.9, 68.4, 42.5, 25.8, 23.5, 23.3, 18.1, -4.5, -4.7; IR (film) *v*: 3358, 1256, 836, 774 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₃H₂₈O₂SiNa [M + Na⁺] 267.1756. Found 267.1751.

(2R,5S,E)-5-(t-Butyldimethylsilyloxy)hex-3-en-2-yl Carbamate (11a). To a solution of alcohol 6a (1.89 g, 8.2 mmol) in dry CH₂Cl₂ (30 mL) cooled to -10 °C, neat TCA-NCO (1.88 g, 1.2 mL, 10.0 mmol) was added. The progress of the reaction was followed by TLC (20% AcOEt/hexanes). After 1 h, the solvent was removed under diminished pressure. The residue was dissolved in MeOH (40 mL) and water (10 mL), and K₂CO₃ (4.2 g, 30.0 mmol) was added. The progress of the reaction was followed by TLC (20% AcOEt/hexanes). After 2 h, MeOH was removed under diminished pressure and the aqueous solution was extracted with CH2Cl2. The combined organic extracts were dried over Na2SO4, and the solvent was removed under diminished pressure. The residue was chromatographed on silica gel (20% AcOEt/hexanes) to afford 2.13 g of carbamate 11a (95%) as a colorless oil. $\left[\alpha\right]_{D}^{24}$ +20.3 (c 1.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.70 (ddd, J 15.5, 5.0, 0.8 Hz, 1H, CH=CH), 5.61 (ddd, J 15.5, 6.1, 1.1 Hz, 1H, CH=CH), 5.24 (p, J 6.4 Hz, 1H, CH₃CH), 4.60 (s, 2H, NH₂), 4.30 (p, J 6.0 Hz, 1H, CH₃CH), 1.31 (d, J 6.5 Hz, 3H, CH₃CH), 1.20 (d, J 6.4 Hz, 3H, CH₃CH), 0.89 (s, 9H, t-BuSi), 0.05 (s, 3H, CH₃Si), 0.04 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ: 156.2, 136.4, 128.1, 71.2, 68.5, 25.8, 24.3, 20.4, 18.3, -4.6, -4.8; IR (film) v: 3509, 3248, 3276, 1717 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₁₃H₂₇NO₃SiNa [M + Na⁺] 296.1658. Found 296.1657.

(25,5*R*,*E*)-5-(*t*-Butyldimethylsilyloxy)hex-3-en-2-yl Carbamate (*ent*-11a). Prepared as compound 11a. Yield 872 mg (90%); colorless oil; $[\alpha]_{21}^{D1}$ -19.3 (*c* 2.0, CHCl₃); HRMS (ESI-TOF) *m/z* calcd for C₁₃H₂₇NO₃SiNa [M + Na⁺] 296.1658; Found 296.1655.

(2*R*,5*R*,*E*)-5-((*t*-Butyldimethylsilyl)oxy)-5-phenylpent-3-en-2yl Carbamate (11b). Prepared as compound 11a. Purification by chromatography on silica gel (15% AcOEt/hexanes). Yield 724 mg (90%) starting from 681 mg (2.33 mmol) of alcohol 6b; colorless oil; $[\alpha]_D^{22}$ +40.5 (*c* 1.1, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ: 7.29– 7.16 (m, 5H, Ph), 5.80–5.66 (m, 2H, CH=CH), 5.25–5.17 (m, 1H, CH₃CH), 5.13 (d, *J* 4.7 Hz, 1H, PhCH), 4.64 (s, 2H, NH₂), 1.26 (d, *J* 6.5 Hz, 3H, CH₃CH), 0.86 (s, 9H, *t*-BuSi), 0.02 (s, 3H, CH₃Si), -0.06 (s, 3H, CH₃Si); ¹³C NMR (151 MHz, CDCl₃) δ: 156.4, 143.6, 135.0, 129.1, 128.3, 127.2, 126.1, 74.8, 71.1, 26.0, 20.5, 18.5, -4.4, -4.7; IR (film) *ν*: 3503, 3352, 1718, 1047, 837 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₈H₂₉NO₃SiNa [M + Na⁺] 358.1814. Found 358.1811.

(2*R*,5*S*,*E*)-5-(*t*-Butyldimethylsilyloxy)-6-phenylhex-3-en-2-yl Carbamate (11c). Prepared in the same manner as compound 11a. Purification by chromatography on silica gel (20% AcOEt/hexanes). Yield 783 mg (77%) starting from 890 mg (2.9 mmol) of alcohol 6c; colorless oil; $[\alpha]_{D}^{22}$ +30 (*c* 0.8, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.32–7.10 (m, 5H, Ph), 5.73 (ddd, *J* 15.5, 5.7, 1.0 Hz, 1H, *CH*= CH), 5.58 (ddd, *J* 15.5, 6.2, 1.2 Hz, 1H, CH=CH), 5.23 (p, *J* 6.4 Hz, 1H, BnCHOTBS), 4.59 (s, 2H, NH₂), 4.26 (q, *J* 6.0 Hz, 1H, CH₃CH), 2.83–2.66 (m, 2H, PhCH₂CH), 1.28 (d, *J* 6.5 Hz, 3H, CH₃CH), 0.83 (s, 9H, *t*-BuSi), -0.11 (s, 3H, CH₃Si), -0.21 (s, 3H, CH₃CH), 0.83 (s, 3273, 3204, 1717, 1388, 1255, 1051, 836, 777 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₉H₃₁NO₃SiNa [M + Na⁺] 372.1971. Found 372.1974.

(2R,5R,E)-6-((t-Butyldimethylsilyl)oxy)-5-methylhex-3-en-2yl Carbamate (11d). Prepared in the same manner as compound **11a.** Purification by chromatography on silica gel (15% AcOEt/ hexanes). Yield 1.16 g (97%) starting from 1 g (4.09 mmol) of alcohol **6d**; yellowish oil; $[\alpha]_D^{21} + 20.1$ (*c* 1.09, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ : 5.65 (ddd, *J* 15.6, 6.8, 0.8 Hz, 1H, CH=CH), 5.50 (ddd, *J* 15.6, 6.3, 1.1 Hz, 1H, CH=CH), 5.26–5.18 (m, 1H, CH₃CHO), 4.67–4.52 (br s, 2H, NH2), 3.48 (dd, *J* 9.7, 6.3 Hz, 1H, CHHOTBS), 3.40 (dd, *J* 9.7, 7.0 Hz, 1H, CHHOTBS), 2.37–2.27 (m, 1H, CH₃CHCH₂OTBS), 1.62 (d, *J* 6.4 Hz, 3H, CH₃CHCH₂OTBS), 0.98 (d, *J* 6.8 Hz, 3H, CH₃CHO), 0.88 (s, 9H, 3 × CH₃C), 0.03 (s, 6H, 2 × CH₃Si); ¹³C NMR (100 MHz, CDCl₃) δ : 156.3, 135.1, 129.4, 71.8, 67.78, 38.8, 26.9, 25.9, 20.5, 18.3, 16.2, -5.36, -5.39; IR (film) *v*: 3501, 3442, 3341, 3205, 1717, 1379, 1050, 833 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₄H₂₉NO₃SiNa [M + Na⁺] 310.1814. Found 310.1813.

(2*R*,6*R*,*E*)-6-((*t*-Butyldimethylsilyl)oxy)hept-3-en-2-yl Carbamate (11e). Prepared in the same manner as compound 11a. Purification by chromatography on silica gel (10% AcOEt/hexanes). Yield 870 mg (74%) starting from 770 mg (4.1 mmol) of alcohol 6e; colorless oil; $[\alpha]_{22}^{D}$ +9.9 (*c* 2.0, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ : 5.73–5.65 (m, 1H, CH=CH), 5.48 (ddt, *J* 15.5, 6.4, 1.2 Hz, 1H, CH=CH), 5.24–5.15 (m, 1H, CH), 4.55 (s, 2H, NH₂), 3.86–3.71 (m, 1H, CH), 2.21–2.07 (m, 2H, CH₂), 1.29 (d, *J* 6.5 Hz, 3H, CH₃), 1.10 (d, *J* 6.1 Hz, 3H, CH₃), 0.87 (s, 9H, *t*-BuSi), 0.03 (s, 3H, CH₃Si), 0.03 (s, 3H, CH₃Si); ¹³C NMR (151 MHz, CDCl₃) δ : 156.2, 131.7, 129.7, 71.7, 68.3, 42.6, 25.8, 23.5, 20.4, 18.1, -4.5, -4.8; IR (film) *v*: 3509, 3447, 3347, 3203, 1714, 1377, 1049, 835 cm⁻¹; HRMS (ESI-TOF) *m*/*z* C₁₄H₂₉NO₃SiNa [M + Na⁺] 310.1814. Found 310.1811.

(2*S*,5*S*,*E*)-5-(*t*-Butyldimethylsilyloxy)hex-3-en-2-yl Carbamate (12a). Prepared in the same manner as compound 11a. Purification by chromatography on silica gel (20% AcOEt/hexanes). Yield 1.85 g (97%) starting from 1.61 g (7 mmol) of alcohol 7a; colorless oil. $[a]_{2^{4.5}}^{24.5}$ -23.5 (*c* 1.41, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.70 (dd, *J* 15.5, 5.0 Hz, 1H, CH=CH), 5.61 (ddd, *J* 15.5, 5.9, 1.1 Hz, 1H, CH=CH), 5.24 (m, 1H, CH), 4.72 (s, 2H, NH₂), 4.28 (m, 1H, CH), 1.30 (d, *J* 6.5 Hz, 3H, CH₃), 1.20 (d, *J* 6.4 Hz, 3H, CH₃), 0.89 (s, 9H, *t*-BuSi), 0.08–0.02 (m, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ: 156.4, 136.2, 128.1, 71.0, 68.5, 25.8, 24.2, 20.4, 18.2, -4.6, -4.8; IR (film) *v*: 3507, 3349, 1716 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₃H₂₇NO₃SiNa [M + Na⁺] 296.1658; Found 296.1656.

(2*R*,5*R*,E)-5-(*t*-Butyldimethylsilyloxy)hex-3-en-2-yl Carbamate (*ent*-12a). Prepared as compound 11a. Yield 660 mg (91%); colorless oil. $[\alpha]_D^{22}$ +23.0 (*c* 1.2 CHCl₃); HRMS (ESI-TOF) *m*/*z* calcd for C₁₃H₂₇NO₃SiNa [M + Na⁺] 296.1658. Found 296.1656.

(25,5*R*,*E*)-5-((*t*-Butyldimethylsilyl)oxy)-5-phenylpent-3-en-2yl Carbamate (12b). Prepared in the same manner as compound 11a. Purification by chromatography on silica gel (15% AcOEt/ hexanes). Yield 737 mg (92%) starting from 700 mg (2.4 mmol) of alcohol 7b; colorless oil; $[\alpha]_D^{24} - 2.8$ (*c* 1.1, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ: 7.27–7.16 (m, 5H, Ph), 5.78–5.65 (m, 2H, CH= CH), 5.25–5.18 (m, 1H, CH₃CH), 5.12 (d, *J* 5.0 Hz, 1H, PhCH), 4.58 (br s, 2H, NH₂), 1.26 (d, *J* 6.5 Hz, 3H, CH₃CH), 0.86 (s, 9H, *t*-BuSi), 0.02 (s, 3H, CH₃Si), -0.06 (s, 3H, CH₃Si); ¹³C NMR (151 MHz, CDCl₃) δ: 156.4, 143.7, 134.8, 129.2, 128.3, 127.2, 126.2, 74.9, 70.9, 26.0, 20.5, 18.5, -4.4, -4.7; IR (film) *v*: 3492, 3347, 3273, 1717, 1052 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₈H₂₉NO₃SiNa [M + Na⁺] 358.1814. Found 358.1812.

(25,55,*E*)-5-(*t*-Butyldimethylsilyloxy)-6-phenylhex-3-en-2-yl Carbamate (12c). Prepared in the same manner as compound 11a. Purification by chromatography on silica gel (20% AcOEt/hexanes). Yield 1.3 g (95%) starting from 1.2 g (3.92 mmol) of alcohol 7c; as colorless oil; $[\alpha]_D^{25}$ -27.3 (*c* 3.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.31–7.12 (m, SH, Ph), 5.73 (ddd, *J* 15.5, 5.8, 1.1 Hz, 1H, CH=CH), 5.59 (ddd, *J* 15.5, 6.2, 1.2 Hz, 1H, CH=CH), 5.23 (p, *J* 6.2 Hz, 1H, CHOTBS), 4.61 (br s, 2H, NH₂), 4.25 (q, *J* 6.0 Hz, 1H, CHOCONH₂), 2.81–2.68 (m, 2H, PhCH₂CH), 1.27 (d, *J* 6.5 Hz, 3H, CHCH₃); ¹³C NMR (126 MHz, CDCl₃) δ : 156.4, 138.6, 134.7, 130.1, 129.6, 128.1, 126.3, 74.2, 71.2, 45.2, 25.9, 20.6, 18.3, -4.6, -5.1; IR (film) ν : 3504, 3342, 3273, 1718, 1387, 1053, 836, 778 cm⁻¹; HRMS

(ESI-TOF) m/z calcd for $C_{19}H_{31}NO_3SiNa$ [M + Na⁺] 372.1971. Found 372.1977.

(2*R*,5*R*,*E*)-6-((*t*-Butyldimethylsilyl)oxy)-5-methylhex-3-en-2yl Carbamate (12d). Prepared in the same manner as compound 11a. Purification by chromatography on silica gel (20% AcOEt/ hexanes). Yield 933 mg (79%) starting from 1 g (4.09 mmol) of compound 7d; yellowish oil; $[\alpha]_{23}^{23}$ -11.3 (*c* 1.25, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.63 (dd, *J* 15.7, 7.1 Hz, 1H, CH=CH), 5.49 (dd, *J* 15.7, 6.4 Hz, 1H, CH=CH), 5.25–5.18 (m, 1H, CH₃CHOCONH₂), 4.60 (s, 2H, NH₂), 3.47 (dd, *J* 9.7, 6.3 Hz, 1H, TBSOCHH), 3.40 (dd, *J* 9.7, 6.8 Hz, 1H, TBSOCHH), 2.36–2.26 (m, 1H, CHCH₃), 1.30 (d, *J* 6.4 Hz, 3H, CH₃CHOCONH₂), 0.99 (d, *J* 6.8 Hz, 3H, CH₃CH), 0.89 (s, 9H, *t*-BuSi), 0.03 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ 156.5, 135.4, 129.6, 72.0, 67.9, 39.1, 26.1, 20.7, 18.5, 16.5, -5.19, -5.22; IR (film) *v*: 3344, 1715, 1372, 1040, 832, 777 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₄H₂₉NO₃SiNa [M + Na⁺] 310.1814. Found 310.1806.

(25,6*R*,*E*)-6-((*t*-Butyldimethylsilyl)oxy)hept-3-en-2-yl Carbamate (12e). Prepared in the same manner as compound 11a. Purification by chromatography on silica gel (15% AcOEt/hexanes). Yield 1.09 g (84%) starting from 1.1 g (4.5 mmol) of alcohol 7e; colorless oil; $[\alpha]_{D}^{23}$ –25.7 (*c* 0.64, CHCl₃); ¹H NMR (500 MHz, CDCl3) δ : 5.68 (dtd, *J* 15.6, 7.3, 1.1 Hz, 1H, CH=CH), 5.49 (dd, *J* 15.5, 6.4 Hz, 1H, CH=CH), 5.20 (qt, *J* 6.7, 3.3 Hz, 1H, CH), 4.55 (s, 2H, NH₂), 3.84–3.82 (m, 1H, CH), 2.22–2.14 (m, 1H, CHH), 2.14–2.05 (m, 1H, CHH), 1.29 (d, *J* 6.5 Hz, 3H, CH₃), 1.10 (d, *J* 6.1 Hz, 3H, CH₃), 0.86 (s, 9H, *t*-BuSi), 0.02 (s, 3H, CH₃Si), 0.02 (s, 3H, CH₃Si), ¹³C NMR (126 MHz, cdcl₃) δ 156.3, 131.7, 129.5, 71.7, 68.4, 42.6, 25.8, 23.5, 20.4, 18.1, –4.5, –4.7; IR (film) *v*: 3349, 1717, 1377, 1049, 836, 775 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₄H₂₉-NO₃SiNa [M + Na⁺] 310.1814. Found 310.1809.

Methyl ((2S,3R,E)-2-((t-Butyldimethylsilyl)oxy)hex-4-en-3yl)carbamate (15). To a solution of carbamate 11a (100 mg, 0.366 mmol) and Et₃N (222 mg, 305 μ L, 2.196 mmol) in dry THF (5 mL) cooled to -20 °C, TFAA (153 mg, 111 μ L, 0.732 mmol) was added, and the resulting mixture was slowly warmed to room temperature. The progress of the reaction was followed by TLC (20% AcOEt in hexanes). In a separate flask, a 1 M soln. of LiHMDS in THF (2.2 mL, 2.2 mmol) was added to anhydr. MeOH (2 mL) in dry THF (5 mL). When the rearrangement reaction was completed (ca. 1 h), the solution of MeOLi was cannulated, and reaction mixture was stirred overnight at room temperature. The progress of the reaction was followed by TLC (20% AcOEt in hexanes). After removal of solvents, the crude product was absorbed on silica gel and chromatographed (10% AcOEt in hexanes) to give 100 mg of carbamate 15 (95%) as a colorless oil. $[\alpha]_{D}^{23}$ -7.6 (c 0.64, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.66 (dd, J 15.4, 6.4 Hz, 1H, CH=CHCH₃), 5.42 (ddd, J 15.4, 7.7, 1.4 Hz, 1H, CH=CHCH₃), 4.89 (s, 1H, NH), 4.04-3.82 (m, 2H, 2 × CH), 3.66 (s, 3H, CH₃O), 1.70 (dd, J 6.4, 1.4 Hz, 3H, CH=CHCH₃), 1.06 (d, J 6.2 Hz, 3H, CH₃CH), 0.89 (s, 9H, t-BuSi), 0.05 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 158.9, 131.8, 129.3, 72.9, 61.4, 54.6, 28.4, 23.0, 20.7, 20.5, -1.7, -2.3; IR (film) v: 3334, 1714, 1254, 835 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₁₄H₂₉NO₃SiNa [M + Na⁺] 310.1814. Found 310.1820.

Methyl ((25,35,*E*)-2-((*t*-Butyldimethylsilyl)oxy)hex-4-en-3-yl)carbamate (18). Prepared in the same manner as compound 15. Purification by chromatography on silica gel (10% AcOEt in hexanes). Yield 103 mg (86%) starting from 100 mg (0.366 mmol) of compound 12a; colorless oil; $[\alpha]_D^{22} + 0.5$ (*c* 0.9, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 5.65–5.55 (m, 1H, CH=CHCH₃), 5.41 (ddd, *J* 15.3, 6.1, 1.6 Hz, 1H, CH=CHCH₃), 4.99 (s, 1H, NH), 4.03–3.91 (m, 1H, CH), 3.89–3.81 (m, 1H, CH), 3.68 (s, 3H, CH₃C), 1.70–1.67 (m, 3H, CH=CHCH₃), 1.14 (d, *J* 6.2 Hz, 3H, CH₃CH), 0.88 (s, 9H, *t*-BuSi), 0.04 (s, 3H, CH₃Si), 0.02 (s, 3H, CH₃Si); ¹³C NMR (151 MHz, CDCl₃) δ : 156.9, 130.6, 126.1, 70.5, 58.0, 52.0, 25.7, 20.9, 18.0, 17.6, -4.5, -4.9; IR (film) *v*: 3449, 3341, 1733, 1718, 1504, 1254, 1070, 835, 776 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₄H₂₉NO₃SiNa [M + Na⁺] 310.1814; Found 310.1814.

Benzyl ((25,3*R*,*E*)-2-((*t*-Butyldimethylsilyl)oxy)hex-4-en-3-yl)carbamate (19). To a cooled to -20 °C solution of carbamate 11a

(150 mg, 0.55 mmol) and Et_3N (333 mg, 460 μ L, 3.29 mmol) in dry THF (10 mL), TFAA (230 mg, 150 μ L, 1.1 mmol) was added, and the resulting mixture was slowly warmed to room temperature. The progress of the reaction was followed by TLC (20% AcOEt in hexanes). In a separate flask, a 1 M soln. of LiHMDS in THF (3.3 mL, 3.29 mmol) was added to anhydr. BnOH (350 μ L) in 10 mL of THF. When rearrangement was completed (ca. 1 h), the solution of BnOLi was cannulated, and the reaction mixture was stirred overnight at room temperature. The progress of the reaction was followed by TLC (10% AcOEt in hexanes). After removal of solvents, the crude product was supported on silica gel and chromatographed (5% AcOEt in hexanes) to give 138 mg of carbamate 19 (76%) as a colorless oil; $[\alpha]_{\rm D}^{22}$ -3.3 (c 0.87, CHCl₃); ¹H NMR (500 MHz, DMSO- d_6) δ : 7.34–7.23 (m, 5H, Ph), 7.09 (d, J 8.1 Hz, 1H, NH), 5.47 (dd, J 16.0, 6.4 Hz, 1H, CH= CH), 5.36 (dd, J 16.0, 6.6 Hz, 1H, CH=CH), 5.01-4.93 (m, 2H, PhCH2O), 3.80-3.65 (m, 2H, CHOTBS, CHNHCbz), 1.59 (d, J 6.2 Hz, 3H, CH₂), 0.98 (d, J 6.1 Hz, 3H, CH₂), 0.80 (s, 9H, t-BuSi), -0.03 (s, 3H, CH₃Si), -0.05 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, DMSO d_6) δ : 155.5, 137.3, 129.2, 128.3, 127.7, 127.6, 126.43, 69.9, 65.1, 59.0, 25.7, 20.2, 17.7, 17.6, -4.6, -4.9; IR (film) v: 3450, 3334, 1723, 1255, 835, 776 $\rm cm^{-1};$ HRMS (ESI-TOF) m/z calcd for $\rm C_{20}H_{33}NO_3SiNa$ [M + Na⁺] 386.2127. Found 386.2126.

Benzyl ((2*R*,35,*E*)-2-((*t*-Butyldimethylsilyl)oxy)hex-4-en-3-yl)carbamate (*ent*-19). Prepared in the same manner as compound 19. Yield 163 mg (80%); colorless oil; $[\alpha]_D^{22}$ +3.5 (*c* 0.95, CHCl₃); HRMS (ESI-TOF) *m*/*z* calcd for C₂₀H₃₃NO₃SiNa [M + Na⁺] 386.2127. Found 386.2125.

Benzyl ((15,2*R*,*E*)-1-((*t*-Butyldimethylsilyl)oxy)-1-phenylpent-3-en-2-yl)carbamate (25). Prepared in the same manner as compound 19; Purification by chromatography on silica gel (5% AcOEt in hexanes); Yield 183 mg (77%) starting from 200 mg (0.56 mmol) of carbamate 11b; colorless oil; $[\alpha]_{D^2}^{2D}$ +61.8 (*c* 1.3, CHCl₃); ¹H NMR (500 MHz, C₆D₆) δ: 7.40–6.97 (m, 10H, 2 × Ph), 5.42 (dd, J 15.3, 6.8 Hz, 1H, CH=CH), 5.33–5.22 (m, 1H, CH=CH), 5.14 (d, J 12.3 Hz, 1H, OCHHPh), 5.09 (d, J 12.3 Hz, 1H, OCHHPh), 4.99 (br s, 1H, NH), 4.84 (d, J 8.0 Hz, 1H, CH), 4.58–4.47 (m, 1H, CH), 1.38 (br d, J 6.3 Hz, 3H, CH₃CH=CH), 0.93 (s, 9H, *t*-BuSi), 0.03 (s, 3H, CH₃Si), -0.14 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, C₆D₆, signals at range 129.5–127.7 ppm were omitted due to overlapping with solvent residual peaks) δ: 155.6, 142.0, 137.5, 127.5, 126.8, 77.1, 66.7, 60.2, 26.0, 25.9, 18.4, 17.7, -4.6, -5.0; IR (film) *v*: 3451, 3332, 1724, 1495, 1255, 834, 697 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₅H₃₅-NO₃SiNa [M + Na⁺] 448.2284. Found 448.2285.

Benzyl ((2*S*,3*R*,*E*)-2-((*t*-Butyldimethylsilyl)oxy)-1-phenylhex-4-en-3-yl)carbamate (27). Prepared in the same manner as compound 19. Purification by chromatography on silica gel (5% AcOEt in hexanes). Yield 215 mg (82%) starting from 200 mg (0.572 mmol) of compound 11c; colorless oil; $[\alpha]_{2^3}^{2^3}$ -4.3 (*c* 1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 7.53–6.97 (m, 10H, 2 × Ph), 5.75–5.61 (m, 1H, CH=CH), 5.58–5.45 (m, 1H, CH=CH), 5.14–5.02 (m, 2H, OCH₂Ph), 4.94 (s, 1H, NH), 4.12–3.94 (m, 2H, 2 × CH), 2.82– 2.58 (m, 2H, CH₂Ph), 1.75 (d, *J* 5.5 Hz, 3H, CH₃CH=CH), 0.86 (s, 9H, *t*-BuSi), 0.00 (s, 3H, CH₃Si), -0.26 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ 155.4, 138.0, 136.7, 130.0, 129.5, 128.4, 128.4, 128.3, 127.9, 126.4, 126.3, 75.5, 66.5, 57.0, 40.7, 25.9, 18.1, 18.0, -4.7, -4.9; IR (film) *v*: 3453, 3335, 1720, 1497, 1254, 835, 698 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₆H₃₈NO₃Si [M + H⁺] 440.2621. Found 440.2618.

Benzyl ((*2R*,*3R*,*E*)-1-((*t*-Butyldimethylsilyl)oxy)-2-methylhex-4-en-3-yl)carbamate (44a). Prepared in the same manner as compound 19. Purification by chromatography (4% AcOEt in hexanes). Yield 176 mg (88%) starting from 150 mg (0.522 mmol) of compound 11d; yellowish oil; $[\alpha]_D^{22}$ +7.2 (*c* 1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.37–7.27 (m, 5H, Ph), 5.84 (s, 1H, NH), 5.66–5.56 (m, 1H, CH₃CH=CH), 5.39 (dd, *J* 15.0, 5.6 Hz, 1H, CH₃CH=CH), 5.16–5.04 (m, 2H, CH₂OPh), 4.17–4.09 (m, 1H, CHNHCbz), 3.80–3.71 (m, 1H, TBSOCHHCH), 3.48 (dd, *J* 10.0, 4.3 Hz, 1H, TBSOCHHCH), 1.78–1.71 (m, 1H, CH₃CH), 1.69 (d, *J* 6.4 Hz, 3H, CH₃CH=CH), 0.99 (d, *J* 6.9 Hz, 3H, CH₃CH), 0.89 (s, 9H, (CH₃)₃CSi), 0.04 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz,

CDCl₃) δ : 156.1, 137.0, 130.5, 128.3, 127.75, 127.72, 126.1, 66.2, 65.1, 56.6, 38.4, 25.8, 18.1, 17.7, 14.4, -5.71, -5.73; IR (film) ν : 3409, 3334, 1726, 1712, 1086 cm⁻¹; HRMS (ESI-TOF) m/z calcd for C₂₁H₃₅-NO₃SiNa [M + Na⁺] 400.2284. Found 400.2288.

Benzyl ((4*S*,6*R*,*E*)-6-((*t*-Butyldimethylsilyl)oxy)hept-2-en-4yl)carbamate (44b). Prepared in the same manner as compound 19. Purification by chromatography on silica gel (6% AcOEt in hexanes). Yield 230 mg (87%) starting from 200 mg (0.697 mmol) of compound 11e; colorless oil; $[\alpha]_{22}^{D2}$ -16.5 (*c* 3.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.36–7.28 (m, 5H, Ph), 5.66–5.54 (m, 1H, CH=CH), 5.49–5.34 (m, 1H, CH=CH), 5.16–5.02 (m, 2H, 2 × CH), 4.26–4.17 (m, 1H), 4.05–3.91 (m, 1H), 1.68 (d, *J* 6.3 Hz, 3H, CH₃), 1.15 (d, *J* 6.1 Hz, 3H, CH₃), 0.89 (s, 9H, *t*-BuSi), 0.06 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 155.7, 136.9, 131.5, 128.3, 127.9, 127.8, 125.6, 66.3, 66.1, 50.7, 44.1, 25.9, 23.9, 17.9, 17.6, -4.1, -4.8; IR (film) *v*: 3330, 1709, 1528, 1255, 836, 775 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₁H₃₅NO₃SiNa [M + Na⁺] 400.2284. Found 400.2282.

Benzyl ((25,35,*E*)-2-((*t*-Butyldimethylsilyl)oxy)hex-4-en-3-yl)carbamate (22). Prepared in the same manner as compound 19. Purification by chromatography on silica gel (10% AcOEt in hexanes); Yield 140 mg (70%) starting from 150 mg (0.549 mmol) of compound 12a; colorless oil; $[\alpha]_{D}^{23}$ –12.1 (*c* 1.21, CHCl₃); ¹H NMR (500 MHz, PhMe-*d*₇, 70 °C) δ : 7.26–6.94 (m, 5H, Ph), 5.56–5.45 (m, 1H, CH= CH), 5.36 (dd, *J* 15.4, 4.6 Hz, 1H, CH=CH), 5.12–4.99 (m, 2H, PhCH₂O), 4.86–4.75 (m, 1H, NH), 4.20–4.07 (m, 1H, CH), 3.79– 3.67 (m, 1H, CH), 1.53 (d, *J* 6.4 Hz, 3H, CH₃CH), 1.03 (d, *J* 6.0 Hz, 3H, CH₃CH), 0.86 (s, 9H, *t*-BuSi), –0.03 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 156.3, 136.7, 130.5, 128.5, 128.4, 128.1, 128.0, 128.0, 126.3, 70.6, 66.7, 58.2, 25.8, 20.9, 18.0, 17.6, –4.5, –4.9; IR (film) *v*: 3445, 3331, 1727, 1494, 1097 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₂₀H₃₃NO₃SiNa [M + Na⁺] 386.2127. Found 386.2123.

Benzyl ((2*R*,3*R*,*E*)-2-((*t*-Butyldimethylsilyl)oxy)hex-4-en-3-yl)carbamate (*ent*-22). Prepared in the same manner as compound 19. Yield 155 mg (75%); colorless oil; $[\alpha]_{2}^{D4}$ +11.8 (*c* 1.1, CHCl₃); HRMS (ESI-TOF) *m*/*z* calcd for C₂₀H₃₃NO₃SiNa [M + Na⁺] 386.2127. Found 386.2123.

Benzyl ((15,25,*E***)-1-((***t***-Butyldimethylsilyl)oxy)-1-phenylpent-3-en-2-yl)carbamate (26). Prepared in the same manner as compound 19. Purification by chromatography on silica gel. Yield 127 mg (67%) starting from 150 mg (0.448 mmol) of compound 12b; colorless oil; [\alpha]_D^{21} +20.1 (***c* **1.09, CHCl₃); ¹H NMR (500 MHz, CDCl₃) \delta: 7.39–7.24 (m, 10H, 2 × Ph), 5.67–5.55 (m, 1H, CH= CH), 5.49 (ddd,** *J* **15.3, 5.9, 1.6 Hz, 1H, CH=CH), 5.06–4.95 (m, 3H, CH, OCH₂Ph), 4.75 (s, 1H, NH), 4.35–4.20 (m, 1H, CH), 1.69 (d,** *J* **6.4 Hz, 3H, CH₃CH=CH), 0.89 (s, 9H,** *t***-BuSi), 0.02 (s, 3H, CH₃Si), -0.13 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) \delta: 155.8, 141.5, 136.6, 129.4, 128.4, 128.3, 128.0(x2), 127.9, 127.4, 126.9, 126.3(x2), 66.5, 59.1, 25.8, 18.2, 17.7, -4.7, -5.1; IR (film)** *v***: 3447, 336, 1724, 1499, 1096 cm⁻¹; HRMS (ESI-TOF)** *m/z* **calcd for C₂₅H₃₅NO₃SiNa [M + Na⁺] 448.2284. Found 448.2284.**

Benzyl ((25,35,*E*)-2-((*t*-Butyldimethylsilyl)oxy)-1-phenylhex-4-en-3-yl)carbamate (28). Prepared in the same manner as compound 19. Purification by chromatography (10% AcOEt in hexanes). Yield 153 mg (60%) starting from 200 mg (0.573 mmol) of compound 12c; colorless oil; $[\alpha]_{D}^{25}$ –6.3 (*c* 0.65, CHCl₃); ¹H NMR (500 MHz, DMSO-*d*₆/CD₃OD 4:1) δ : 7.44–7.00 (m, 10H, 2 × Ph), 5.68–5.43 (m, 2H, CH=CH), 5.11–5.02 (m, 2H, OCH₂Ph), 4.14– 4.04 (m, 1H, CH), 3.82–3.71 (m, 3H), 2.83 (dd, *J* 13.4, 2.8 Hz, 1H, CHHPh), 2.37 (dd, *J* 13.4, 9.0 Hz, 1H, CHHPh), 1.66 (d, *J* 5.7 Hz, 3H, CH₃CH=CH), 0.75 (s, 9H, *t*-BuSi), –0.11 (s, 3H, CH₃Si), –0.50 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, DMSO-*d*₆) δ : 155.6, 139.1, 137.1, 129.4, 128.3, 127.9, 127.8, 127.7, 127.7, 126.3, 125.9, 75.8, 65.3, 56.7, 38.7, 25.6, 17.7, 17.6, –5.0, –5.6; IR (film) *v*: 3444, 3340. 1724, 1497, 1086 cm-¹; HRMS (TOF-ESI) *m*/*z* calcd for C₂₆H₃₇NO₃SiNa [M + Na⁺] 462.2440. Found 462.2434.

Benzyl ((2*R*,3*S*,*E*)-1-((*t*-Butyldimethylsilyl)oxy)-2-methylhex-4-en-3-yl)carbamate (42a). Prepared in the same manner as compound 19. Purification by chromatography (4% AcOEt in hexanes). Yield 173 mg (87%) starting from 150 mg (0.522 mmol) of compound **12d**; colorless oil; $[\alpha]_D^{22}$ +4.3 (*c* 1.8, CHCl₃)¹H NMR (500 MHz, CDCl₃) δ : 7.38–7.26 (m, 5H, Ph), 5.97 (d, *J* 6.8 Hz, 1H, NH), 5.63 (m, 1H, CH₃CH=CH), 5.38 (ddd, *J* 15.3, 6.6, 1.3 Hz, 1H, CH₃CH=CH), 5.16–4.98 (m, 2H, OCH₂Ph), 4.14 (m, 1H, CHNHCbz), 3.53 (ps t, *J* 10.1, 9.1 Hz, 1H, CHHOTBS), 3.47 (dd, *J* 10.1, 4.9 Hz, 1H, CHHOTBS), 2.04–1.91 (m, 1H, CH₃CH), 1.71 (d, *J* 6.3 Hz, 3H, CH₃CH=CH), 0.90 (s, 9H, (CH₃)₃CSi), 0.81 (d, *J* 7.1 Hz, 3H, CH₃CH), 0.05 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 155.6, 137.0, 128.3, 127.8, 127.7, 127.5, 66.2, 65.8, 56.4, 39.0, 25.8, 18.1, 17.8, 13.6, –5.7; IR (film) *v*: 3415, 3334, 1726, 1712, 1504, 1252, 1094, 837, 776 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₁H₃₅NO₃SiNa [M + Na⁺] 400.2284. Found 400.2284.

Benzyl ((4*R*, 6*R*,*E*)-6-((**i**-Butyldimethylsilyl)oxy)hept-2-en-4yl)carbamate (42b). Prepared in the same manner as compound 19. Purification by chromatography on silica gel (10% AcOEt in hexanes). Yield 206 mg (78%) starting from 200 mg (0.697 mmol) of compound 12e; colorless oil; $[\alpha]_{D}^{21}$ –9.3 (*c* 0.81, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ : 7.35–7.27 (m, 5H, Ph), 5.70–5.52 (m, 1H, CH=CH), 5.44–5.29 (m, 1H, CH=CH), 5.18–4.98 (m, 2H, OCH₂Ph), 4.80 (s, 1H, NH), 4.23–4.08 (m, 1H, CH), 3.92–3.76 (m, 1H, CH), 1.72–1.60 (m, 5H, CH₂, CH₃CH=CH), 1.14 (d, J 5.6 Hz, 3H, CH₃), 0.85 (s, 9H, *t*-BuSi), 0.02 (s, 3H, CH₃Si), 0.00 (s, 3H, CH₃Si); ¹³C NMR (151 MHz, CDCl₃) δ : 136.6, 131.7, 128.4, 128.0, 126.2, 126.0, 66.5, 58.1, 50.9, 45.4, 25.9, 24.1, 18.0, 17.7, –4.1, –4.7; IR (film) *v*: 3330, 1708, 1530, 1254, 836, 774 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₁H₃₅NO₃SiNa [M + Na⁺] 400.2284. Found 400.2285.

t-Butyl ((2S,3R,E)-2-((t-Butyldimethylsilyl)oxy)hex-4-en-3-yl)carbamate (20). To a cooled to -20 °C solution of carbamate 11a (150 mg, 0.55 mmol) and Et₃N (333 mg, 460 μ L, 3.29 mmol) in dry THF (10 mL), TFAA (230 mg, 150 μ L, 1.1 mmol) was added, and the resulting mixture was warmed to room temperature slowly. The progress of the reaction was followed by TLC (20% AcOEt in hexanes). In a separate flask, a 1 M soln. of LiHMDS in THF (3.3 mL, 3.29 mmol) was added to anhydr. t-BuOH (0.5 mL) in dry THF (10 mL). When rearrangement was completed (ca. 1 h), the solution of t-BuOLi was cannulated, and the reaction mixture was stirred overnight at room temperature. The progress of the reaction was followed by TLC (20% AcOEt in hexanes). After removal of solvents, the crude product was supported on silica gel and chromatographed (10% AcOEt in hexanes) to give 151 mg of carbamate 20 (84%) as a colorless oil. $[\alpha]_D^{22}$ +4.8 (c 1.4, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 5.72-5.54 (m, 1H, CH₃CH=CH), 5.41 (ddd, J 15.3, 7.7, 1.3 Hz, 2H, CH₃CH=CH), 4.73 (s, 1H, NH), 4.03-3.73 (m, 2H, CHOTBS, CHNHBoc), 1.70 (dd, J 6.5, 1.3 Hz, 3H, CH₃CH=CH), 1.43 (s, 9H, (CH₃)₃CO), 1.05 (d, J 6.3 Hz, 3H, CH₃CH), 0.90 (s, 9H, (CH₃)₃CSi), 0.06 (s, 3H, CH₃Si), 0.05 (s, 3H, CH₃Si); $^{13}\mathrm{C}$ NMR (126 MHz, CDCl₃) δ: 158.1, 130.1, 126.7, 70.3, 28.4, 25.8, 20.4, 18.0, 17.9, -4.4, -4.9; IR (film) v: 3458, 3349, 1716, 1494, 1175, 835, 776 cm⁻¹ HRMS (ESI-TOF) m/z calcd for $C_{17}H_{35}NO_3SiNa$ [M + Na⁺] 352.2284. Found 352.2275.

t-Butyl ((25,35,*E*)-2-((*t*-Butyldimethylsilyl)oxy)hex-4-en-3-yl)carbamate (23). Prepared in the same manner as compound 20. Purification by chromatography on a short pad of silica gel (20% AcOEt in hexanes). Yield 138 mg (76%) starting from 150 mg (0.549 mmol) of compound 12a; yellowish oil; $[\alpha]_{D}^{22}$ – 13.0 (*c* 0.48, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.62–5.52 (m, 1H, CH=CH), 5.40 (ddd, *J* 15.4, 5.8, 1.3 Hz, 1H, CH=CH), 4.89–4.71 (m, 1H, CH), 4.01–3.88 (m, 1H, NH), 3.89–3.79 (m, 1H, CH), 1.68 (d, *J* 6.4 Hz, 3H, CH₃), 1.45 (s, 9H, *t*-BuO), 1.13 (d, *J* 6.2 Hz, 3H, CH₃), 0.88 (s, 9H, *t*-BuSi), 0.04 (s, 3H, CH₃Si), 0.02 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ: 155.9, 130.9, 125.7, 100.0, 70.7, 28.4, 25.8, 20.8, 18.0, 17.6, -4.4, -4.8; IR (film) *v*: 3453, 1721, 1494, 1173, 835, 776 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₇H₃₅NO₃SiNa [M + Na⁺] 352.2284. Found 352.2283.

N-((2*S*,3*R*,*E*)-2-((*t*-Butyldimethylsilyl)oxy)hex-4-en-3-yl)acetamide (21). To a cooled to -20 °C solution of carbamate 11a (300 mg, 1.1 mmol) and Et₃N (668 mg, 920 μ L, 6.6 mmol) in dry THF (10 mL), TFAA (462 mg, 305 μ L, 2.2 mmol) was added, and the resulting mixture was warmed to room temperature slowly. The

progress of the reaction was followed by TLC (20% AcOEt in hexanes). After 1 h, a solution was cooled to -10 °C and a 3 M soln. of MeMgBr (6.6 mmol, 2.2 mL) was added. After 4 h, the reaction was quenched by addition of sat. aq. NH₄Cl. The organic layer was separated, and the aqueous one was extracted with CH2Cl2. After removal of solvents, the crude product was supported on silica gel and chromatographed (25% AcOEt in hexanes) to give 250 mg of carbamate 21 (83%) as a colorless oil. $[\alpha]_{D}^{23}$ -21.2 (c 0.86, CHCl₃); ¹H NMR (500 MHz, C₆D₆) δ: 5.59–5.49 (m, 1H, CH=CH), 5.43 (ddd, J 15.4, 8.0, 1.5 Hz, 1H, CH=CH), 5.21 (br d, J 7.0 Hz, 1H, NH), 4.42 (td, J 8.3, 3.2 Hz, 1H, CHCH=CH), 3.84 (qd, J 6.3, 3.4 Hz, 1H, CH₃CH), 1.60 (s, 3H, CH₃CO), 1.49 (dd, J 6.3, 1.1 Hz, 3H, CH₃CH=CH), 0.93 (d, J 6.3 Hz, 3H, CH₃), 0.89 (s, 9H, t-BuSi), -0.05 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, C₆D₆) δ : 167.2, 129.1, 126.8, 70.2, 56.9, 25.6, 22.8, 20.3, 17.8, 17.6, -4.7, -5.2; IR (film) v: 3282, 1649, 1550, 835, 775 cm⁻¹; HRMS (ESI-TOF) m/zcalcd for C14H29NO2SiNa [M + Na⁺] 294.1865. Found 294.1864.

N-((2*S*,3*S*,*E*)-2-((*t*-Butyldimethylsilyl)oxy)hex-4-en-3-yl)acetamide (24). Prepared in the same manner as compound 21. Purification by chromatography on silica gel (25% AcOEt in hexanes). Yield 184 mg (92%) starting from 200 mg (0.731 mmol) of compound 12a; colorless oil; $[\alpha]_D^{22} -2.1$ (*c* 2.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.76 (d, *J* 7.2 Hz, 1H, NH), 5.62–5.53 (m, 1H, CH=CH), 5.43–5.35 (m, 1H, CH=CH), 4.33–4.25 (m, 1H, CHCH=CH), 3.92–3.82 (m, 1H, CHCH₃), 2.03 (s, 3H, CH₃CO), 1.67 (d, *J* 6.4 Hz, 3H, CH₃CH=CH), 1.11 (d, *J* 6.2 Hz, 3H, CH₃CO), 1.67 (d, *J* 6.4 Hz, CDCl₃) δ: 169.6, 130.3, 126.2, 70.5, 56.0, 25.8, 23.5, 21.0, 18.0, 17.6, -4.4, -4.9; IR (film) *v*: 3289, 1651, 1094, 835 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₄H₃₀NO₂Si [M + H⁺] 272.2046. Found 272.2044.

Methyl O-(t-Butyldimethylsilyl)-N-(methoxycarbonyl)-L-allothreoninate (29). Ozone was passed through a stirred solution of carbamate 15 (50 mg, 0.185 mmol) in 10 mL of CH₂Cl₂ and 0.64 mL of 2.5 M methanolic NaOH at -70 °C. The progress of the reaction was followed by TLC (AcOEt/hexane 1:4). After 1 h, yellow precipitation occurred and reaction mixture became blue. At this point, oxygen was bubbled through the reaction mixture for 20 min. It was than diluted with water (15 mL) and CH₂Cl₂ (15 mL), and the resulting mixture was warmed slowly to room temperature. The organic layer was separated, and the aqueous one was extracted with CH_2Cl_2 (3 × 15 mL). The combined organic layers were dried over anhydrous Na₂SO₄, and the solvent was removed under diminished pressure. The residue was chromatographed on silica gel to (20% AcOEt in hexanes) to afford 47 mg of product 29 (85%) as a paleyellow oil. $[\alpha]_{D}^{22}$ +25.4 (c 1.3, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ: 5.41 (d, J 7.3 Hz, 1H, NH), 4.29-4.21 (m, 1H, CHNH), 4.10-4.00 (m, 1H, CHOTBS), 3.71 (s, 3H, CH₃O), 3.65 (s, 3H, CH₃O), 1.21 (d, J 6.4 Hz, 3H, CH₃CH), 0.83 (s, 9H, t-BuSi), 0.02 (s, 3H, CH₃Si), 0.01 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ: 170.5, 156.3, 69.8, 60.0, 52.3, 52.0, 25.6, 20.4, 17.8, -4.6, -5.2; IR (film) v: 3443, 3345, 1732, 1512, 1254, 835, 777 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₃H₂₈NO₅Si [M + H⁺] 306.1737. Found 306.1732.

Methyl *N*-((Benzyloxy)carbonyl)-*O*-(*t*-butyldimethylsilyl)-*Lallo*-threoninate (31). Prepared in the same manner as compound 25. Purification by chromatography on silica gel to (20% AcOEt in hexanes). Yield 75 mg (71%) starting from 100 mg (0.275 mmol) of compound 19; colorless oil; $[\alpha]_D^{25} + 22$ (*c* 3.65, CHCl₃) [lit.⁵¹ + 27.3 (*c* 0.55, CH₂Cl₂)]; ¹H NMR (500 MHz, CDCl₃) δ : 7.40–7.29 (m, 5H, Ph), 5.50 (d, *J* 7.2 Hz, 1H, NH), 5.20–5.06 (m, 2H, OCH₂Ph), 4.35– 4.26 (m, 1H, CH), 4.16–4.05 (m, 1H, CH), 3.74 (s, 3H, COOCH₃), 1.24 (d, *J* 6.3 Hz, 3H, CH₃CH), 0.86 (m, 9H, *t*-Bu), 0.04 (s, 3H, CH₃), 0.03 (s, 3H, CH₃); ¹³C NMR (126 MHz, CDCl₃) δ : 170.5, 155.8, 136.5, 128.6, 128.3, 128.2, 70.01, 67.1, 60.2, 52.2 25.7, 20.6, 18.0, –4.4, –5.0; IR (film) *v*: 3441, 3354, 1730, 1507 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₉H₃₁NO₅SiNa [M + Na⁺] 404.1869. Found 404.1870.

Methyl N-((Benzyloxy)carbonyl)-O-(t-butyldimethylsilyl)-Dallo-threoninate (ent-31). Prepared in the same manner as compound 25. Yield 53 mg (73%); colorless oil; $[\alpha]_{D}^{22}$ -21 (c 1.5, CHCl₃); HRMS (ESI-TOF) m/z calcd for $C_{19}H_{31}NO_{5}SiNa$ [M + Na⁺] 404.1869. Found 404.1861.

Methyl *N*-(*tert*-Butoxycarbonyl)-O-(*t*-butyldimethylsilyl)-*Lallo*-threoninate (32). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (20% AcOEt in hexanes). Yield 58 mg (92%) starting from 60 mg (0.182 mmol) of compound 20; colorless oil; $[\alpha]_{2^3}^{D^3}$ +33.8 (*c* 0.7, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ : 5.25 (*d*, *J* 7.5 Hz, 1H, NH), 4.26–4.17 (m, 1H, CHNH), 4.10–4.01 (m, 1H, CHOTBS), 3.73 (s, 3H, CH₃O), 1.43 (s, 9H, *t*-BuO), 1.22 (*d*, *J* 6.4 Hz, 3H, CH₃CH), 0.85 (s, 9H, *t*-BuSi), 0.03 (s, 6H, 2 × CH₃Si); ¹³C NMR (151 MHz, CDCl₃) δ : 170.7, 155.1, 79.8, 69.9, 59.6, 52.0, 28.3, 25.6, 20.5, 17.9, -5.1; IR (film) *v*: 3447, 3365, 1747, 1719, 1499, 1167, 836, 777 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₆H₃₃NO₅SiNa [M + Na⁺] 370.2026. Found 370.2018.

Methyl N-Acetyl-O-(*t*-butyldimethylsilyl)-L-*allo*-threonate (33). Prepared in the same manner as compound 25. Purification by chromatography on silica gel to (20% AcOEt in hexanes). Yield 130 mg (82%) starting from 150 mg (0.55 mmol) of compound 21; colorless oil; $[\alpha]_D^{25}$ +52.8 (*c* 1.16, CHCl₃) [lit.⁵² +47 (*c* 0.32, CHCl₃)]; ¹H NMR (500 MHz, CDCl₃) δ : 6.20 (d, *J* 8.0 Hz, 1H, NH), 4.53 (dd, *J* 8.1, 3.4 Hz, 1H, CHNHCbz), 4.08 (qd, *J* 6.4, 3.4 Hz, 1H, CH₃CH), 3.75 (s, 3H, CH₃O), 2.02 (s, 3H, CH₃CO), 1.26 (d, *J* 6.4 Hz, 3H, CH₃CH), 0.87 (s, 9H, *t*-BuSi), 0.04 (s, 3H, CH₃Si), 0.04 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 170.6, 169.5, 70.1, 58.5, 52.2, 25.8, 23.4, 20.9, 18.0, -4.4, -4.9; IR (film) *v*: 3289, 1747, 1660, 1546, 1256, 835 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₃H₂₇-NO₄SiNa [M + Na⁺] 312.1607. Found 312.1611.

Methyl (25,35)-2-(((Benzyloxy)carbonyl)amino)-3-((t-butyldimethylsilyl)oxy)-3-phenylpropanoate (38). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (20% AcOEt in hexanes); Yield 40 mg (86%) starting from 37 mg (0.106 mmol) of compound 25; colorless oil; $[\alpha]_D^{23}$ +75.9 (*c* 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.36–7.27 (m, 10H, 2 × Ph), 5.30 (br d, *J* 7.6 Hz, 1H, NH), 5.06 (br d, *J* 4.2 Hz, 1H, PhCHOTBS), 4.59 (br dd, *J* 8.5, 4.3 Hz, 1H, CHNH), 3.66 (s, 3H, CH₃O), 3.64–3.60 (m, 2H, OCH₂Ph), 0.89 (s, 9H, *t*-BuSi), 0.06 (s, 3H, CH₃Si), -0.14 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 170.2, 156.2, 140.1, 139.4, 128.1(x3), 127.9, 126.2(x2), 75.3, 61.1, 52.3, 51.9, 25.6, 18.1, -4.9, -5.4; IR (film) *v*: 3442, 3335, 1733, 1513, 1257, 838, 779 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₄H₃₃-NO₅SiNa [M + Na⁺] 466.2026. Found 466.2029.

Methyl (25,35)-2-(((Benzyloxy)carbonyl)amino)-3-((t-butyldimethylsilyl)oxy)-4-phenylbutanoate (39). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (20% AcOEt in hexanes). Yield 74 mg (89%) starting from 80 mg (0.182 mmol) of compound 26; colorless oil; $[\alpha]_{D}^{23}$ +24.1 (*c* 0.7, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.40–7.19 (m, 10H, 2 × Ph), 5.53 (d, J 6.9 Hz, 1H, NH), 5.09 (br s, 2H, OCH₂Ph), 4.46–4.37 (m, 1H, CHNH), 4.30–4.18 (m, 1H, CHOTBS), 3.79 (s, 3H, CH₃O), 2.93 (dd, J 13.6, 6.3 Hz, 1H, CHHPh), 2.82 (dd, J 13.6, 7.9 Hz, 1H, CHHPh), 0.81 (s, 9H, *t*-BuSi), -0.02 (s, 3H, CH₃Si), -0.33 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 169.4, 160.3, 137.7, 129.7, 128.5, 128.4, 128.1, 128.0, 126.6, 75.2, 66.9, 58.5, 52.2, 40.7, 25.7, 17.9, -4.9, -5.2; IR (film) *v*: 3439, 3362, 1727, 1256, 1101, 837, 777, 699 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₅H₃₆NO₅Si [M + H⁺] 458.2363. Found 458.2363.

Methyl (2*S*,3*R*)-2-(((Benzyloxy)carbonyl)amino)-4-((*t*-butyldimethylsilyl)oxy)-3-methylbutanoate (45a). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (10% AcOEt in hexanes). Yield 52 mg (87%) starting from 60 mg (0.159 mmol) of compound 44a; colorless oil; $[\alpha]_D^{22}$ –1.1 (*c* 0.8, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.44–7.27 (m, 5H, Ph), 6.03 (d, *J* 8.3 Hz, 1H, NH), 5.21–4.97 (m, 2H, OCH₂Ph), 4.35 (dd, *J* 8.6, 4.3 Hz, 1H, CHNH), 3.73 (s, 3H, CH₃O), 3.63 (dd, *J* 10.4, 3.8 Hz, 1H, CHHOTBS), 3.50 (dd, *J* 10.4, 5.5 Hz, 1H, CHHOTBS), 2.24– 2.28 (m, 1H, CHCH₃), 1.03 (d, *J* 7.1 Hz, 3H, CH₃CH), 0.89 (s, 9H, *t*-BuSi), 0.04 (s, 3H, CH₃Si), 0.04 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 172.5, 156.6, 136.5, 128.4, 127.9, 127.7, 66.7, 65.2, 57.8, 52.1, 36.6, 25.8, 18.1, 14.4, –5.7; IR (film) *v*: 3400, 1729, 838 cm⁻¹;

HRMS (ESI-TOF) m/z calcd for $C_{20}H_{34}NO_5Si [M + H^+]$ 396.2206. Found 396.2205.

Methyl (25,4*R*)-2-(((Benzyloxy)carbonyl)amino)-4-((*t*-butyldimethylsilyl)oxy)pentanoate (45b). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (20% AcOEt in hexanes). Yield 58 mg (93%) starting from 60 mg (0.159 mmol) of compound 44b; colorless oil; $[\alpha]_D^{22} - 26.2$ (*c* 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.40–7.28 (m, 5H, Ph), 5.83 (d, *J* 6.7 Hz, 1H, NH), 5.14 (d, *J* 12.5 Hz, 1H, OCHHPh), 5.08 (d, *J* 12.5 Hz, 1H, OCHHPh), 4.46–4.39 (m, 1H, CHNH), 4.01–3.93 (m, 1H, CHOTBS), 3.73 (s, 3H, CH₃O), 1.96–1.86 (m, 1H, CHH), 1.85– 1.77 (m, 1H, CHH), 1.17 (d, *J* 6.1 Hz, 3H, CH₃CH), 0.88 (s, 9H, *t*-BuSi), 0.06 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, cdcl₃) δ 173.0, 156.0, 136.5, 128.4, 127.9, 127.8, 66.7, 66.2, 52.2, 52.1, 40.3, 25.8, 23.8, 17.9, -4.2, -5.0; IR (film) *ν*: 3343, 1725, 1255, 1217, 836, 776 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₀H₃₃NO₅SiNa [M + Na⁺] 418.2026, Found 418.2026.

Methyl O-(t-Butyldimethylsilyl)-*N***-(methoxycarbonyl)-D-threoninate (30).** Prepared in the same manner as compound **25**; Purification by chromatography on silica gel (15% AcOEt in hexanes). Yield 44 mg (88%) starting from 54 mg (0.164 mmol) of compound **18**; colorless oil; $[\alpha]_{D}^{23}$ +14.3 (*c* 1.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 5.35 (*d*, *J* 9.3 Hz, 1H, NH), 4.47–4.39 (m, 1H, CHOTBS), 4.24 (dd, *J* 9.3, 1.5 Hz, 1H, CHNH), 3.72 (*s*, 3H, CH₃O), 3.71 (*s*, 3H, CH₃O), 1.20 (*d*, *J* 6.3 Hz, 3H, CH₃CH), 0.84 (*s*, 9H, *t*-BuSi), 0.04 (*s*, 3H, CH₃Si), -0.02 (*s*, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 171.4, 157.3, 68.8, 59.9, 52.4, 52.2, 25.6, 20.8, 17.8, -4.4, -5.4; IR (film) ν : 3440, 3346, 1729, 1510, 1255, 836, 777 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₃H₂₇NO₅SiNa [M + Na⁺] 328.1556. Found 328.1556.

Methyl *N***-((Benzyloxy)carbonyl)-***O***-(***t***-butyldimethylsilyl)threoninate (34). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (20% AcOEt in hexanes). Yield 85 mg (82%) starting from 100 mg (0.275 mmol) of compound 22; a colorless oil; [\alpha]_D^{25} +8.6 (***c* **0.7, CHCl₃) [lit.⁵¹ +9 (***c* **1, CHCl₃)]; ¹H NMR (500 MHz, CDCl₃) \delta: 7.44–7.29 (m, 5H, Ph), 5.43 (d,** *J* **9.5 Hz, 1H, NH), 5.14 (br s, 2H, OCH₂Ph), 4.50–4.40 (m, 1H, CH₃CHOTBS), 4.28 (dd,** *J* **9.6, 1.6 Hz, 1H, CHNHCbz), 3.73 (s, 3H, OCH₃), 1.21 (d,** *J* **6.3 Hz, 3H, CH₃CH), 0.84 (s, 9H, (CH₃)₃C), 0.04 (s, 3H, CH₃), -0.01 (s, 3H, CH₃); ¹³C NMR (126 MHz, CDCl₃) \delta: 171.3, 156.7, 136.3, 128.5, 128.1, 128.1, 68.8, 67.1, 59.9, 52.2, 25.6, 20.8, 17.8, -4.4, -5.4; IR (film)** *v***: 3448, 3356, 1730, 1507 cm⁻¹; HRMS (ESI-TOF)** *m***/***z* **calcd for C₁₉H₃₁NO₅SiNa [M + Na⁺] 404.1869. Found 404.1866.**

Methyl *N*-((Benzyloxy)carbonyl)-*O*-(*t*-butyldimethylsilyl)-L-threoninate (*ent*-34). Prepared in the same manner as compound 25. Yield 50 mg (83%); colorless oil; $[\alpha]_D^{22} - 8.2$ (*c* 1.1, CHCl₃); HRMS (ESI-TOF) *m*/*z* calcd for C₁₉H₃₁NO₅SiNa [M + Na⁺] 404.1869. Found 404.1865.

Methyl *N*-(*t*-Butoxycarbonyl)-*O*-(*t*-butyldimethylsilyl)threoninate (35). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (20% AcOEt in hexanes). Yield 90 mg (80%) starting from 107 mg (0.325 mmol) of compound 23; colorless oil; $[\alpha]_D^{22}$ +3.3 (*c* 0.6, CHCl3) [lit.⁵³ for *ent*-35: -1.1 (*c* 2.4, CHCl₃)]; ¹H NMR (600 MHz, C₆D₆) δ : 5.54 (d, *J* 9.7 Hz, 1H, NH), 4.59 (dd, *J* 9.9, 1.9 Hz, 1H, CHNH), 4.37 (qd, *J* 6.2, 1.9 Hz, 1H, CH₃CHOTBS), 3.40 (s, 3H, CH₃O), 1.52 (s, 9H, *t*-BuO), 1.17 (d, *J* 6.3 Hz, 3H, CH₃CH), 0.92 (s, 9H, *t*-BuSi), 0.00 (s, 3H, CH₃Si), -0.02 (s, 3H, CH₃Si); ¹³C NMR (151 MHz, C₆D₆) δ : 171.1, 156.0, 79.1, 69.0, 59.5, 51.2, 28.0, 25.4, 20.4, 17.6, -4.8, -5.7; IR (film) *v*: 3457, 1755, 1721, 15000, 1168 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₁₆H₃₃NO₅SiNa [M + Na⁺] 370.2026. Found 370.2020.

Methyl N-Acetyl-O-(t-butyldimethylsilyl)-D-threoninate (36). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (25% AcOEt in hexanes). Yield 65 mg (86%) starting from 70 mg (0.260 mmol) of compound 24; colorless oil; $[\alpha]_{23}^{23}$ -5.3 (c 0.8, CHCl₃) [lit.⁵² for *ent*-36: +6.5 (c 0.02, CH₂Cl₂)]; ¹H NMR (500 MHz, CDCl₃) δ : 6.08 (d, J 9.0 Hz, 1H, NH), 4.54 (dd, J 9.4, 1.8 Hz, 1H, CHNH), 4.41 (qd, J 6.3, 1.8 Hz, 1H, CH₃CHOTBS), 3.69 (s, 3H, CH₃O), 2.06 (s, 3H, CH₃CO), 1.14 (d, J 6.3 Hz, 3H, CH₃CH), 0.82 (s, 9H, *t*-BuSi), 0.02 (s, 3H, CH₃Si), -0.03 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 171.1, 170.4, 68.8, 57.7, 52.2, 25.6, 23.2, 20.8, 17.8, -4.5, -5.4; IR (film) *v*: 3302, 1749, 1662, 1531, 1254, 1096, 838, 777 cm⁻¹; HRMS (ESI-TOF) *m/z* calcd for C₁₃H₂₈NO₄Si [M + H⁺] 290.1788. Found 290.1787.

Methyl (2*R*,3*S*)-2-(((Benzyloxy)carbonyl)amino)-3-((*t*-butyldimethylsilyl)oxy)-3-phenylpropanoate (40). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (20% AcOEt in hexanes). Yield 48 mg (77%) starting from 60 mg (0.141 mmol) of compound 27; colorless oil; $[\alpha]_{D}^{22}$ +46.8 (*c* 1.1, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.41–7.22 (m, 10H, 2 × Ph), 5.51 (d, *J* 9.6 Hz, 1H, NH), 5.32 (s, 1H, PhCH), 5.02–4.91 (m, 2H, OCH₂Ph), 4.49 (dd, *J* 9.8, 1.8 Hz, 1H, CHNH), 3.77 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 170.8, 156.1, 140.4, 136.3, 128.5, 128.1, 128.1, 128.0, 127.8, 126.1, 74.6, 66.9, 61.1, 52.4, 29.7, 25.6, 18.1, -4.7, -5.6; IR (film) *v*: 3308, 1745, 1667, 1536, 1252, 1101, 836, 777 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₄H₃₃-NO₅SiNa [M + Na⁺] 466.2026. Found 466.2029.

Methyl (2*R*,3*S*)-2-(((Benzyloxy)carbonyl)amino)-3-((*t*-butyldimethylsilyl)oxy)-4-phenylbutanoate (41). Prepared in the same manner as compound 25a. Purification by chromatography on silica gel (10% AcOEt in hexanes). Yield 76 mg (82%) starting from 90 mg (0.205 mmol) of compound 28; colorless oil; $[\alpha]_{D}^{23}$ +18.4 (*c* 1.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.47–7.13 (m, 10H, 2 × Ph), 5.47 (d, *J* 9.8 Hz, 1H, NH), 5.22 (d, *J* 12.2 Hz, 1H, OCHHPh), 5.16 (d, *J* 12.2 Hz, 1H, OCHHPh), 4.48–4.36 (m, 1H, BnCHOSi), 4.27 (br d, *J* 9.8 Hz, 1H, CHNH), 3.68 (s, 3H, CH₃O), 2.90–2.74 (m, 2H, CH₂Ph), 0.86 (s, 9H, *t*-BuSi), -0.00 (s, 3H, CH₃Si), -0.04 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 171.6, 156.6, 136.8, 136.4, 129.5, 128.7, 128.5, 128.4, 128.2, 127.6, 126.9, 126.8, 74.3, 67.1, 56.7, 52.2, 41.2, 25.7, 17.9, -4.7, -5.2; IR (film) *v*: 3372, 1723, 834 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₅H₃₅NO₅SiNa [M + Na⁺] 480.2182. Found 480.2180.

Methyl (2*R*,3*R*)-2-(((Benzyloxy)carbonyl)amino)-4-((*t*-butyl-dimethylsilyl)oxy)-3-methylbutanoate (43a). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (25% AcOEt in hexanes). Yield 64 mg (87%) starting from 60 mg (0.159 mmol) of compound 41a; colorless oil; $[\alpha]_D^{23}$ +9.8 (*c* 0.7, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.39–7.27 (m, 5H, Ph), 5.70 (d, *J* 8.5 Hz, 1H, NH), 5.16–5.03 (m, 2H, OCH₂Ph), 4.50 (dd, *J* 8.8, 3.4 Hz, 1H, CHNH), 3.73 (s, 3H, CH₃O), 3.57–3.45 (m, 2H, CH₂OTBS), 0.89 (s, 9H, *t*-BuSi), 0.03 (s, 6H, 2 × CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 172.4, 156.1, 136.4, 128.4, 128.0, 127.9, 66.8, 65.2, 56.2, 52.1, 37.9, 25.8, 18.1, 12.3, -5.6; IR (film) *v*: 3375, 1725, 837 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₀H₃₄NO₅Si [M + H⁺] 396.2206. Found 396.2198.

Methyl (2*R*,4*R*)-2-(((Benzyloxy)carbonyl)amino)-4-((*t*-butyl-dimethylsilyl)oxy)pentanoate (43b). Prepared in the same manner as compound 25. Purification by chromatography on silica gel (10% AcOEt in hexanes). Yield 62 mg (60%) starting from 100 mg (0.265 mmol) of compound 42b; colorless oil; $[\alpha]_D^{22} - 4.8$ (*c* 0.5, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ : 7.42–7.27 (m, 5H, Ph), 5.57 (d, *J* 5.8 Hz, 1H, NH), 5.15–5.10 (m, 2H, OCH₂Ph), 4.43–4.26 (m, 1H, CHNH), 4.10–3.94 (m, 1H, CHOTBS), 3.73 (s, 3H, CH₃O), 2.00–1.80 (m, 2H, CH₂), 1.20–1.16 (m, 4H, CH₃CH), 0.87 (s, 9H, *t*-BuSi), 0.05 (s, 3H, CH₃Si), 0.04 (s, 3H, CH₃Si); ¹³C NMR (126 MHz, CDCl₃) δ : 173.0, 155.8, 136.3, 128.4, 128.0, 128.0, 66.9, 66.4, 52.2, 41.3, 29.7, 25.8, 23.6, 17.9, -4.4, -4.8; IR (film) ν : 3370, 1721, 836 cm⁻¹; HRMS (ESI-TOF) *m*/*z* calcd for C₂₀H₃₃NO₅SiNa [M + Na⁺] 418.2026. Found 418.2019.

ASSOCIATED CONTENT

Supporting Information

Copies of ¹H and ¹³C NMR spectra for selected compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: sebastian.stecko@icho.edu.pl (S.S.).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Author is grateful to Polish Ministry of Science and Higher Education for financial support of research (*Iuventus Plus Grant* No. IP2011 051871 and IP2010 039070). The authors are grateful to The Regional Council of Mazovia and European Union within European Regional Development Fund for a Ph.D. student scholarship (P.S.). The authors are also grateful to The European Union within the Structural Funds No. POKL.04.01.01-00-114/09-01 for a postdoctoral fellowship (A.P.-H.)

REFERENCES

(1) Hughes, A. B., Ed. Amino Acids, Peptides and Proteins in Organic Chemistry: Protection Reactions, Medicinal Chemistry, Combinatorial Synthesis; Wiley: Weinheim, 2011; Vol 4.

(2) Pollegioni, L., Servi, S., Eds. Unnatural Amino Acids; Springer: New York, 2012.

(3) Williams, R. M. Synthesis of Optically Active α -Amino Acids; Pergamon Press: Oxford, U.K., 1989.

(4) Baltz, R. H.; Miao, V.; Wrigley, S. K. Nat. Prod. Rep. 2005, 22, 717–741.

(5) Castanho, M., Santos, N., Eds. Peptide Drug Discovery and Development: Translational Research in Academia and Industry; Wiley: Weinheim, 2011.

(6) Phoenix, D. A.; Dennison, S. R.; Harris, F. Antimicrobial Peptides; Wiley: Weinheim, 2012.

(7) Molinski, V. L. Handbook of Marine Natural Products: Isolation, Structure, Medicine and Synthesis; Wiley & Sons, Inc.: New York, 2012.

(8) Groner, B. Peptides as Drugs: Discovery and Development; Wiley: Weinheim, 2009.

(9) (a) Prakash, A.; Goa, K. BioDrugs 1999, 12, 139–157.
(b) Esposito, P.; Barbero, L.; Caccia, P.; Caliceti, P.; D'Antonio, M.; Piquet, G.; Veronese, F. M. Adv. Drug Delivery Rev. 2003, 55, 1279–1291.

(10) (a) Zaninovic, V.; Gukovskaya, A. S.; Gukovsky, I.; Mouria, M.; Pandol, S. J. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2000**, *279*, G666–G6676. (b) Ibii, N.; Ikeda, M.; Takahara, Y.; Eigyo, M.; Akiyoshi, T.; Matsushita, A. *Peptides* **1989**, *10*, 779–783.

(11) (a) Briones, M.; Bajaj, M. Expert Opin. Pharmacother. 2006, 7, 1055–1064. (b) Mann, R. J.; Nasr, N. E.; Sinfield, J. K.; Paci, E.; Donnelly, D. Br. J. Pharmacol. 2010, 160, 1973–1984.

(12) (a) Lalezari, J. P.; Eron, J. J.; Carlson, M.; Cohen, C.; DeJesus, E.; Arduino, R. C.; Gallant, J. E.; Volberding, P.; Murphy, R. L.; Valentine, F.; Nelson, E. L.; Sista, P. R.; Dusek, A.; Kilby, J. M. *AIDS* (*London, U.K.*) **2003**, *17*, 691–698. (b) Greenberg, M. L.; Cammack, N. J. *Antimicro. Chemother.* **2004**, *54*, 333–340. (c) Fung, H. B.; Guo, Y. *Clin. Ther.* **2004**, *26*, 352–378.

(13) (a) Burke, T. R., Jr; Knight, M.; Chandrasekhar, B.; Ferretti, J. A. *Tetrahedron Lett.* **1989**, *30*, 519–522. (b) Laycock, M. V.; Hildebrand, P. D.; Thibault, P.; Walter, J. A.; Wright, J. L. C. *J. Agric. Food Chem.* **1991**, *39*, 483–489. (c) Saini, H. S.; Barragán-Huerta, B. E.; Lebrón-Paler, A.; Pemberton, J. E.; Vázquez, R. R.; Burns, A. M.; Marron, M. T.; Seliga, C. J.; Gunatilaka, A. A. L.; Maier, R. M. *J. Nat. Prod.* **2008**, *71*, 1011–1015.

(14) (a) Zindel, J.; de Meijere, A. J. Org. Chem. 1995, 60, 2968–2973.
(b) Andres, N.; Wolf, H.; Zähner, H.; Rössner, E.; Zeeck, A.; König, W. A.; Sinnwell, V. Helv. Chim. Acta 1989, 72, 426–437. (c) Rössner, E.; Zeeck, A.; König, W. A. Angew. Chem., Int. Ed. 1990, 29, 64–65.
(d) Hofer, I.; Crusemann, M.; Radzom, M.; Geers, B.; Flachshaar, D.; Cai, X.; Zeeck, A.; Piel, J. Chem. Biol. 2011, 18, 381–91.

(15) (a) Morita, H.; Nagashima, S.; Takeya, K.; Itokawa, H. J. Chem. Soc., Perkin Trans. 1 **1995**, 2327–2331. (b) Rossi, F.; Zanotti, G.; Saviano, M.; Iacovino, R.; Palladino, P.; Saviano, G.; Amodeo, P.; Tancredi, T.; Laccetti, P.; Corbier, C.; Benedetti, E. J. Pept. Sci. **2004**, 10, 92–102.

(16) Ballio, A.; Barra, D.; Bossa, F.; Collina, A.; Grgurina, I.; Marino, G.; Moneti, G.; Paci, M.; Segre, A.; Simmaco, M. *FEBS Lett.* **1991**, *291*, 109–112.

(17) Zampella, A.; D'Auria, M. V.; Paloma, L. G.; Casapullo, A.; Minale, L.; Debitus, C.; Henin, Y. J. Am. Chem. Soc. **1996**, *118*, 6202–6209.

(18) Oku, N.; Gustafson, K. R.; Cartner, L. K.; Wilson, J. A.; Shigematsu, N.; Hess, S.; Pannell, L. K.; Boyd, M. R.; McMahon, J. B. J. Nat. Prod. **2004**, 67, 1407–1411.

(19) Ford, P. W.; Gustafson, K. R.; McKee, T. C.; Shigematsu, N.; Maurizi, L. K.; Pannell, L. K.; Williams, D. E.; Dilip de Silva, E.; Lassota, P.; Allen, T. M.; Van Soest, R.; Andersen, R. J.; Boyd, M. R. J. *Am. Chem. Soc.* **1999**, *121*, 5899–5909.

(20) Plaza, A.; Gustchina, E.; Baker, H. L.; Kelly, M.; Bewley, C. A. J. Nat. Prod. 2007, 70, 1753–1760.

(21) Plaza, A.; Bifulco, G.; Keffer, J. L.; Lloyd, J. R.; Baker, H. L.; Bewley, C. A. J. Org. Chem. **2008**, 74, 504–512.

(22) (a) Nakata, H.; Maeda, K.; Miyakawa, T.; Shibayama, S.; Matsuo, M.; Takaoka, Y.; Ito, M.; Koyanagi, Y.; Mitsuya, H. J. Virol. **2005**, 79, 2087–2096. (b) Nishizawa, R.; Nishiyama, T.; Hisaichi, K.; Matsunaga, N.; Minamoto, C.; Habashita, H.; Takaoka, Y.; Toda, M.; Shibayama, S.; Tada, H.; Sagawa, K.; Fukushima, D.; Maeda, K.; Mitsuya, H. Bioorg. Med. Chem. Lett. **2007**, *17*, 727–731.

(23) Williams, D. H. Acc. Chem. Res. 1984, 17, 364-369.

(24) Jolad, S. D.; Hoffman, J. J.; Torrance, S. J.; Wiedhopf, R. M.; Cole, J. R.; Arora, S. K.; Bates, R. B.; Gargiulo, R. L.; Kriek, G. R. J. Am. Chem. Soc. **1977**, *99*, 8040–8044.

(25) Chênevert, R.; Thiboutot, S. Synthesis 1989, 444-446.

(26) Shoji, J.; Hinoo, H.; Hattori, T.; Hirooka, K.; Kimura, Y.; Yoshida, T. J. Antibiot. **1989**, 42, 1460–1464.

(27) Kato, T.; Hinoo, H.; Terui, Y.; Kikuchi, J.; Shoji, J. J. Antibiot. **1988**, 41, 719–725.

(28) Hanessian, S.; Vakiti, R. R.; Dorich, S.; Banerjee, S.; Deschênes-Simard, B. J. Org. Chem. 2012, 77, 9458–9472.

(29) (a) Zhong, F.; Wang, Y.; Han, X.; Huang, K.-W.; Lu, Y. Org. Lett. 2011, 13, 1310–1313. (b) Xu, L.-W.; Lu, Y. Org. Biomol. Chem.
2008, 6, 2047–2053. (c) Wu, X.; Jiang, Z.; Shen, H.-M.; Lu, Y. Adv. Synth. Catal. 2007, 349, 812–816. (d) Xu, L.-W.; Luo, J.; Lu, Y. Chem. Commun. 2009, 1807–1821. (e) Cheng, L.; Wu, X.; Lu, Y. Org. Biomol. Chem. 2007, 5, 1018–1020.

(30) Mlynarski, J.; Bas, S. Chem. Soc. Rev. 2014, 43, 577-587.

(31) (a) Jung, M. E.; Jung, Y. H. *Tetrahedron Lett.* 1989, 30, 6637–6640. (b) Shao, H.; Goodman, M. J. Org. Chem. 1996, 61, 2582–2583.
(c) Schmidt, U.; Respondek, M.; Lieberknecht, A.; Werner, J.; Fischer, P. Synthesis 1989, 256–261.

(32) (a) Makino, K.; Goto, T.; Hiroki, Y.; Hamada, Y. Tetrahedron: Asymmetry 2008, 19, 2816–2828. (b) Liu, Z.; Shultz, C. S.; Sherwood, C. A.; Krska, S.; Dormer, P. G.; Desmond, R.; Lee, C.; Sherer, E. C.; Shpungin, J.; Cuff, J.; Xu, F. Tetrahedron Lett. 2011, 52, 1685–1688. (33) (a) Singjunla, Y.; Baudoux, J.; Rouden, J. Org. Lett. 2013, 15, 5770–5773. (b) MacMillan, J. B.; Molinski, T. F. Org. Lett. 2002, 4, 1883–1886. (c) Horikawa, M.; Busch-Petersen, J.; Corey, E. J. Tetrahedron Lett. 1999, 40, 3843–3846. (d) Yoshikawa, N.; Shibasaki, M. Tetrahedron 2002, 58, 8289–8298. (e) Lin, N.; Deng, Y.-Q.; Zhang, Z.-W.; Wang, Q.; Lu, G. Tetrahedron: Asymmetry 2014, 25, 650–657.

(34) (a) Kambourakis, S.; Rozzell, J. D. *Tetrahedron* **2004**, *60*, *663*– *669*. (b) Fesko, K.; Giger, L.; Hilvert, D. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 5987–5990. (c) Makart, S.; Bechtold, M.; Panke, S. J. *Biotechnol.* **2007**, *130*, 402–410. (d) Steinreiber, J.; Fesko, K.; Reisinger, C.; Schürmann, M.; van Assema, F.; Wolberg, M.; Mink, D.; Griengl, H. *Tetrahedron* **2007**, *63*, 918–926.

(35) (a) Andrés, J. M.; Martínez, M. a. A.; Pedrosa, R.; Pérez-Encabo,
A. Tetrahedron: Asymmetry 2001, 12, 347–353. (b) Seo, Y.; Kim, H.;
Chae, D. W.; Kim, Y. G. Tetrahedron: Asymmetry 2014, 25, 625–631.
(36) (a) Swift, M. D.; Sutherland, A. Tetrahedron Lett. 2007, 48,

3771–3773. (b) Jamieson, A. G.; Sutherland, A. *Tetrahedron* 2007, *63*, 2123–2131.

(37) Kikuchi, M.; Konno, H. Tetrahedron 2013, 69, 7098-7101.

(38) (a) Horner, L.; Hoffmann, H. M. R.; Wippel, H. G. Chem. Ber. 1958, 91, 61–63. (b) Horner, L.; Hoffmann, H. M. R.; Wippel, H. G.; Klahre, G. Chem. Ber. 1959, 92, 2499–2505. (c) Wadsworth, W. S.; Emmons, W. D. J. Am. Chem. Soc. 1961, 83, 1733–1738. (d) Boutagy, J.; Thomas, R. Chem. Rev. 1974, 74, 87–99. (e) Maryanoff, B. E.; Reitz, A. B. Chem. Rev. 1989, 89, 863–927.

(39) (a) Corey, E. J.; Bakshi, R. K.; Shibata, S. J. Am. Chem. Soc. 1987, 109, 5551–5553. (b) Corey, E. J.; Bakshi, R. K.; Shibata, S.; Chen, C. P.; Singh, V. K. J. Am. Chem. Soc. 1987, 109, 7925–7926.

(40) (a) Nakamura, K.; Matsuda, T. Enzymatic Kinetic Resolution. In *Enantiomer Separation*; Toda, F., Ed.; Springer: Netherlands, 2004; pp 231–266. (b) Vulfson, E. N.; Halling, P. J.; Holland, H. L. *Enzymes in Nonaqueous Solvents: Methods and Protocols*; Humana Press: New York, 2001.

(41) (a) Luche, J. L. J. Am. Chem. Soc. 1978, 100, 2226–2227.
(b) Gemal, A. L.; Luche, J. L. J. Am. Chem. Soc. 1981, 103, 5454–5459.
(42) Stecko, S. J. Org. Chem. 2014, 79, 6342–6346.

(43) (a) Ichikawa, Y. Synlett 1991, 238–240. (b) Ichikawa, Y.; Tsuboi, K.; Isobe, M. J. Chem. Soc., Perkin Trans. 1 1994, 2791–2796. (c) Ichikawa, Y.; Kobayashi, C.; Isobe, M. J. Chem. Soc., Perkin Trans. 1 1996, 377–382. (d) Ichikawa, Y.; Osada, M.; I. Ohtani, I.; Isobe, M. J. Chem. Soc., Perkin Trans. 1 1997, 1449–1456. (e) Ichikawa, Y. Synlett 2007, 2927–2936.

(44) (a) Overman, L. E. J. Am. Chem. Soc. 1974, 96, 597–599.
(b) Overman, L. E. J. Am. Chem. Soc. 1976, 98, 2901–2910.
(c) Nishikawa, T.; Asai, M.; Ohyabu, N.; Isobe, M. J. Org. Chem. 1998, 63, 188–192. (d) Overman, L. E.; Carpenter, N. E. The Allylic Trihaloacetimidate Rearrangement. In Organic Reactions; John Wiley & Sons, Inc.: Hoboken, NJ, 2004.

(45) Marshall, J. A.; Garofalo, A. W.; Sedrani, R. C. Synlett 1992, 643-645.

(46) Massad, S. K.; Hawkins, L. D.; Baker, D. C. J. Org. Chem. 1983, 48, 5180-5182.

(47) Ren, H.; Wulff, W. D. Org. Lett. 2012, 15, 242-245.

(48) Kobayashi, Y.; Takemoto, Y.; Kamijo, T.; Harada, H.; Ito, Y.; Terashima, S. *Tetrahedron* **1992**, *48*, 1853–1868.

(49) Kalesse, M.; Chary, K. P.; Quitschalle, M.; Burzlaff, A.; Kasper, C.; Scheper, T. *Chem.*—*Eur. J.* **2003**, *9*, 1129–1136.

(50) Tartaglia, S.; Padula, D.; Scafato, P.; Chiummiento, L.; Rosini, C. J. Org. Chem. 2008, 73, 4865–4873.

(51) Jackson, R. F. W.; Palmer, N. J.; Wythes, M. J. Tetrahedron Lett. 1994, 35, 7433-7434.

(52) Kuwano, R.; Okuda, S.; Ito, Y. J. Org. Chem. 1998, 63, 3499–3503.

(53) Muir, J. C. Synthesis 1998, 613-618.